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ABSTRACT 
In the last years, evidence accumulated showing a direct connection between brain 
inflammation and neurodevelopmental disorders such as autism and schizophrenia. 
Epilepsy and seizures episodes, in particular, are associated to enhanced brain 
inflammation, while the activation of the immune response consequent to infections 
strongly increases the risk of seizures. 
By using the Poly I:C (polyinosinic-polycytidylic acid) mouse model of maternal 
immune activation (MIA), we demonstrated that a single administration at 
gestational day 9 (GD9) is able to affect the glutamate-GABA equilibrium in the 
offspring through a long-lasting deregulation of the chloride transporter KCC2 at 
cortical level, resulting in an alteration of the hyperpolarizing action of GABA, which 
endures at mature stages, as highlighted by the increased seizure susceptibility. 
Furthermore, mice injected with Poly I:C during adult life show no differences in 
susceptibility to kainate-induced seizures respect to control mice, thus providing 
the evidence that the increased susceptibility to seizures following prenatal Poly I:C 
exposure is the consequence of a neurodevelopmental process. We also provide the 
proof-of-concept that KCC2 expression abnormality and its deleterious 
physiological consequences can be prevented by dietary maternal supplementation 
with MgSO4, already known to reduce inflammation at the maternal-fetal interface. 
Notably, the increased binding of the two master regulators of neuronal genes 
expression, REST and MeCP2, on KCC2 promoter, suggests a possible epigenetic 
mechanism involved in the regulation of KCC2 expression following inflammation 
in the mother. Thus, maternal immune activation, through pro-inflammatory 
cytokines, may lead to epigenetic modifications responsible for KCC2 dysregulation 
and the consequent pathological outcomes, as suggested also by in vitro 
experiments. 
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RIASSUNTO 
Negli ultimi anni, numerose evidenze hanno dimostrato come esista un 
collegamento diretto tra infiammazione nel cervello e disturbi del neurosviluppo, 
tra cui autismo e schizofrenia. Epilessia e convulsioni, in particolare, sono associati 
a un’aumentata infiammazione a livello cerebrale, mentre l'attivazione della 
risposta immunitaria in seguito a infezioni aumenta fortemente il rischio di 
sviluppare episodi convulsivi. 
Mediante l’iniezione di acido polinosinico-policitidilico (Poly I:C), un RNA sintetico 
a doppio filamento, utilizzato come modello di attivazione immunitaria materna nel 
topo, siamo stati in grado di dimostrare come una singola somministrazione al nono 
giorno di gestazione sia in grado di alterare l'equilibrio tra glutammato e GABA nella 
prole attraverso la deregolazione del trasportatore ionico KCC2, coinvolto nel 
mantenimento dell’omeostasi dello ione cloruro a livello neuronale,  con la 
conseguente alterazione dell'azione iperpolarizzante del GABA, che perdura nelle 
fasi mature, come evidenziato dalla maggiore suscettibilità alle convulsioni indotte 
da acido kainico osservata nella prole adulta. Inoltre, i topi iniettati con la stessa 
dose di Poly I:C in età adulta non mostrano un’aumentata suscettibilità alle crisi 
epilettiche indotte dall’iniezione di acido kainico rispetto ai topi di controllo, 
fornendo così la prova che l'aumento della suscettibilità alle crisi epilettiche in 
seguito alla somministrazione prenatale di Poly I:C è la conseguenza di alterazioni a 
livello del neurosviluppo. Inoltre, siamo stati in grado di dimostrare che le anomalie 
riscontrate nell’espressione di KCC2 e le sue deleterie conseguenze a livello 
fisiologico possono essere prevenute grazie all’integrazione, nella dieta materna, di 
MgSO4, già noto in letteratura per la sua capacità di ridurre l'infiammazione 
all’interfaccia materno-fetale. 
Inoltre, l'aumento del legame di REST e MeCP2, due fondamentali regolatori 
dell’espressione di geni neuronali, al promotore del gene codificante per KCC2, 
suggerisce un possibile meccanismo epigenetico coinvolto nella regolazione 
dell'espressione di KCC2 nella prole, in seguito a infiammazione prenatale. 
L’attivazione del sistema immunitario materno, attraverso la produzione di 
citochine pro-infiammatorie, può quindi portare a modificazioni epigenetiche 
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responsabili delle alterazioni dell’espressione di KCC2 e dei conseguenti esiti 
patologici, come suggerito anche da esperimenti in vitro condotti su colture 
neuronali primarie ottenute da embrioni sottoposti a Poly I:C prenatale. 
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INTRODUCTION 
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Chapter 1 
 
MATERNAL IMMUNE ACTIVATION: IMPLICATIONS AND MODELS 
 
Epidemiological evidence 
The developing brain is highly sensitive to several environmental insults, such as 
maternal stress and nutritional deficiencies, that can induce damaging effects in the 
future child [1]. Among these insults, infection-induced maternal immune activation 
(MIA) during pregnancy represent one of the most dangerous. Indeed, MIA can 
contribute to the onset of causal chains of events potentially leading to several 
pathophysiological changes in the fetal environment that can contribute to postnatal 
brain dysfunctions at different ages in the progeny (Figure 1).  
 
 
Figure 1. Causal chain of events following MIA in humans. MIA can lead to a variety of neuronal 
dysfunctions and behavioural phenotypes observable in the juvenile, adult or aged progeny. Modified 
from Knuesel et al. 2014. 
 
 
Several epidemiological studies, that all together examined from 86000 to 124000 
children, confirmed that infections occurring during pregnancy, caused by different 
pathogenic agents, are associated with an increased incidence of psychiatric and 
neurological disorders in the offspring. These include neurodevelopmental 
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disorders such as schizophrenia, autism and epilepsy, as well as neurodegenerative 
pathologies like Alzheimer and Parkinson’s diseases. Thus, inflammatory processes 
in the mother can strongly impact on neuronal circuits development in the fetus and 
the nature, the intensity, the timing and the modality of the exposure to the 
inflammatory stimulus, together with genetic predispositions, can define the cluster 
of symptoms and consequently the phenotype of the neurological disorder that the 
future child can face.  
Regarding schizophrenia, that together with autism seems to be particularly 
sensitive to early inflammatory insults to the central nervous system (CNS), strong 
epidemiological associations have been found between various infectious agents, 
including influenza virus, and the number of schizophrenia cases in the progeny. In 
a paper from Brow et al. published in 2004 [2], it is shown that the risk of developing 
schizophrenia in the progeny is increased 7-fold following influenza virus exposure 
during early phases of pregnancy. Increased levels of influenza antibodies and pro-
inflammatory cytokines, such as IL6, TNF, CXCL8 [3] as well as C-reactive protein 
[4] in the mothers serum were strongly associated with the increased risk for 
schizophrenia in the children. Thanks to these kind of retrospective studies it has 
been possible to estimate that 14-21% of whole cases of schizophrenia could be 
avoidable if we could prevent infections in the mothers during pregnancy [5]. 
Influenza virus is not the only pathogenic agent that shows strong correlation with 
this pathology; Toxoplasma gondii [6], herpes simplex virus type 2 [7] as well as 
urinary tract infection and other types of infections have been found to have a strong 
epidemiological association with schizophrenia when contracted during pregnancy.  
As for schizophrenia, epidemiological studies support the association between 
Autistic Spectrum Disorders (ASD) and different pathogenic agents [8, 9]. Birth 
cohort studies have associated ASD in children with inflammatory markers found in 
utero [10] and/or maternal hospitalization for infections, as well as with the 
presence, in the maternal blood, of antibodies against fetal brain antigens [11-13]. 
Moreover, the CHARGE trial, a big case-control study linked to the University of 
California–Davis Center for Children’s Environmental Health laboratories, found 
that women who contracted influenza during pregnancy are more prone to have 
children with ASD [14]. Moreover, the “winter baby” phenomenon, reported by the 
California Department of Developmental Services, describes a higher risk for autism 
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spectrum disorders in babies conceived during the cold winter months [15], 
possibly due to higher infection rates in the mothers during this period.  
 
Animal models of MIA 
Epidemiology alone is not able to identify causal links between maternal immune 
activation and the risk of neurodevelopmental and neurological disorders in the 
offspring. On the other hand, clinical research is limited in the possibility to identify 
the molecular pathways involved because of the ethical and technical impossibility 
to perform invasive experimentation on humans. Furthermore, there is not a 
successful and valid way to identify at-risk pregnancies in order to investigate 
specific aspects of infections during pregnancy. Often at-risk pregnancies are 
symptomless and in any case most of times they lead to healthy children, in which 
symptoms of CNS disorders appears only after some years, usually exacerbated by 
“second hits” [16, 17]. Thus, preclinical research based on animal models results 
essential to overcome these limiting problems and it is the best reason why 
neurological disorders epidemiology needs neurobiology, as discussed particularly 
for schizophrenia in a paper from McGrath and Richard in 2009 [18]. Experimental 
research in animals represents a unique opportunity to identify causal downstream 
cellular and molecular mechanisms involved, possible diagnostic tools and 
pharmacological therapies. Indeed, a causal relationship between maternal immune 
activation and autism/schizophrenia-related behavioural alterations has been 
clearly demonstrated by using rodent models of MIA and, more recently, non-human 
primate models.  
Generally, these models consist in the administration of specific infectious and 
inflammatory agents in pregnant animals at specific gestational stages. Fatemi et al. 
[19] were the first to develop an experimental model of exposure to human 
influenza virus in mice, consisting in a single intranasal administration of the virus 
in pregnant dams at gestational day 9. The offspring was then evaluated for 
behavioural and brain long-term effects respect to control mice. Subsequently, this 
model was also used to study the impact of prenatal timing by administering the 
virus at different gestational days [19]. Thanks to this pioneer mouse model, 
scientists could identify several neuropathological sings in the offspring brains 
postnatally and interestingly some of these signs were found to be depending upon 
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timing of prenatal immune activation. These pathological signs include: deficient 
corticogenesis and brain atrophy, impaired development of the corpus callosum, 
reduced hippocampal size and decreased expression of GABAergic markers such as 
Reelin [20, 21], as well as alterations in serotonin production [22]. Exposure of the 
mother to the human influenza virus also leads to behavioural and cognitive 
abnormalities in the adult offspring, some of which, like for example reduced 
sensorimotor gating, social behaviour and exploratory behaviour, are highly 
relevant for schizophrenia and related psychotic illnesses [23]. This translational 
research was then extended to non-human primates, in particular to rhesus 
monkeys, where prenatal corticogenesis is more advanced as compared with mice. 
Therefore, primate models helped to confirm the relevance of findings obtained in 
rodents and taken together all the information collected can be taken as 
experimental evidence supporting causal effects of prenatal infection with influenza 
virus in long lasting brain defects. 
More recently, new animal models of prenatal immune activation have been 
developed in which the use of living viral or bacterial pathogens have been replaced 
by immune-activating compounds [23]. These compounds are able to induce a 
cytokine-associated immune response and were initially used to study the possible 
key role of cytokines in mediating the link between maternal immune activation and 
abnormal brain development in the offspring [24, 25]. These “simplified” models, 
which include also the administration of individual cytokines, enable a more direct 
study and comprehension of the molecular mechanisms underlying long-lasting 
modifications in the offspring brains after MIA. They offer the possibility to monitor 
the response to the compounds by appropriate dose-response and time-dependent 
studies, thanks to their time-limited effect, usually 24-48 hours from the 
administration [26, 27]. Moreover, it is important to consider that these compounds, 
like LPS and Poly I:C, two of the most used, are commercially available and they can 
be easily handled without particular biosafety precautions. In general, each MIA 
animal model should possess three important characteristics: face validity – they 
have to show pathological signs similar to the ones that are found in humans, 
construct validity – they should have an etiology similar to the human pathology, 
predictive validity – they should respond to treatments that are already successful in 
humans [28].  
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The Poly I:C model of MIA 
One of the most commonly used approaches nowadays is represented by the 
maternal administration of Poly I:C (polyinosinic:polycytidylic acid), a synthetic 
analogue of double strand RNA that mimics the response to viral infections. During 
viral infections, double strand RNA is generated as a replication intermediate for 
single strand RNA. Through the binding to the specific toll-like receptor 3 (TLR3), a 
member of the super-family of pathogen recognition receptors, Poly I:C leads to the 
expression of several genes and proteins linked to the innate immune response; 
different pro-inflammatory molecules including cytokines (IL6 and IL1beta), TNF-
alfa as well as type I interferons are induced by Poly I:C administration [27, 29] 
(Figure 2). 
 
 
 
Figure 2. The Poly I:C MIA model in rodents. Responses in the maternal compartment include systemic 
immune activation characterized by increased levels of proinflammatory cytokines. Consequently, the 
integrity of the placental barrier could be compromised, allowing entrance of maternally derived 
cytokines into the fetal circulation and inducing inflammatory responses in the developing fetus, 
including the brain. This leads to structural and developmental dysfunctions associated with various 
neuropsychiatric diseases. Modified from Reisinger et al. 2015. 
 
 
IL-1β INFβ 
TNFα 
Inflammatory 
response 
Poly I:C 
TLR3 
IL-6 
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Therefore, Poly I:C efficiently mimics the acute phase response to viral infections, 
leading to significant inflammatory processes in the mother and consequently in the 
fetus, when administered systemically [30]. Poly I:C-induced MIA leads to numerous 
structural, neurochemical but also behavioural and cognitive alterations in adult 
offspring overlapping with well-known pathophysiological features of psychotic 
disorders. An interesting aspect to be taken into account is that especially 
behavioural, cognitive and pharmacological features appear in the offspring only in 
late adolescence/early adulthood [31, 32], consistent with the post-pubertal onset 
of psychotic behaviour in schizophrenic patients [33]. Another important aspect of 
Poly I:C prenatal immune activation is that the severity of the phenotype, in terms 
of long-term brain and behavioural changes, is strongly dependent upon the 
intensity of the cytokines-associate immune response [25, 34]. Intense prenatal 
stimuli are associated with more severe brain abnormalities in the offspring [35] 
and there are suggestions indicating that a threshold of immune activation is 
required to induce log-term brain and behavioural changes in the offspring. It is 
possible that low doses of prenatal Poly I:C may not induce a sufficient maternal 
cytokine response able to drive the behavioural features in the offspring. This may 
explain why not all humans exposed to a prenatal infection develop schizophrenia 
in adulthood [36, 37]. Thus, it could be reasonable to think of Poly I:C and other 
compounds used in MIA animal models as models of particular neurobehavioral 
phenotypes, rather than models for specific mental illness [38]. Furthermore, just as 
Tan et al. wrote in the incipit of their paper in 2008 “genes do not encode for 
psychopathology” [39] and harmful environmental stimuli (such as prenatal 
infection) alone do not lead to mental illness. Rather, they can be seen as events 
which are associated with an increased frequency of alterations in brain 
morphology and function, underlying particular behavioural manifestations, which 
are generally associated with particular neuropsychiatric disorders.  
 
MIA as a disease primer for neurological disorders  
It is well established that in humans most of maternal infections alone are not able 
to induce neuropsychiatric disorders in the offspring. It is reasonable to consider 
these pathologies as “multiple hits pathologies”, in which a multiple exposure to 
more than one risk factor may be necessary for the disease onset [40]. 
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Converging recent findings suggest that MIA can act as a “neurodevelopmental 
disease primer” making an individual more susceptible to the effect of genetic 
mutations or environmental stimuli in driving disease-related symptoms later in life 
[41]. Consistent with this hypothesis, epidemiological data indicate that the 
incidence of both schizophrenia and ASD is increased in families with auto-immune 
disorders [42] and the effect of maternal infections is greater in families with a 
history of schizophrenia [43]. Moreover, low doses of Poly I:C in animal models 
synergize with mutations in schizophrenia/autism-linked genes including DISC1 
(Disrupted in schizophrenia 1), NRG1 (neuregulin1), NR4A2 (Nurr1) and TSC2 
(Tuberin), determining a greater effect compared to the inflammatory stimulus 
alone [17, 44]. Studies of interaction between MIA and environmental risk factors 
suggest that even subclinical maternal infections can render the offspring more 
susceptible to second hits. For example, peri-pubertal stress can have synergetic 
effects with subclinical MIA in a wide range of schizophrenia/autism-related 
phenotypes [44] and also cannabis exposure during adolescence can exacerbate 
subclinical effects of MIA in the offspring [45]. Although the molecular basis of MIA 
are still unclarified, specific epigenetic alterations in loci related to neuropsychiatric 
disorders (such as DISC1), consequent to prenatal inflammation, may represent a 
molecular signature of its priming effect [46, 47].  
All considered, two are the possible scenarios by which MIA can work: early-life 
immune challenge may act as disease primer in offspring with genetic 
predisposition by exacerbating brain and behavioural abnormalities [48]; secondly 
MIA may render the offspring more susceptible to the pathological effects of a 
second postnatal hit [49]. 
 
Timing of prenatal immune activation 
Pregnancy in humans represents a paradox for the maternal immune system which 
has to protect the mother from infections but at the same time can potentially attack 
the antigenically foreign fetus [50]. Thus, the maternal immune system exhibits 
considerable fluctuations as pregnancy proceeds and the changes in cytokine 
production following an inflammatory stimulus, may therefore differentially impact 
the developing fetus. This make reasonable to think that depending on the 
gestational period the developing nervous system of the fetus may not be uniformly 
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vulnerable to maternal infections. Indeed, several epidemiological studies identified 
the time-window that goes from the end of the first trimester to the beginning of the 
second one critical to viral exposure, that could possibly lead to the development of 
neuropsychiatric disorders in the post-pubertal period [51]. For example, a study of 
registers, “the Danish medical birth register”, highlighted that maternal infections 
contracted within the first trimester and resulting in the hospitalization of the 
pregnant woman, correspond to a 3-fold increase in the incidence of ASD in the 
progeny [52]. 
Moreover, considering the highly complex and precisely orchestrated processes 
involved in fetal neurodevelopment, starting with proliferation and migration of 
cells, followed by synaptogenesis, myelination but also synapses remodelling 
through pruning, formation of neural circuits and so on, inflammation in the mother 
can affect several important aspects of brain development depending upon time of 
maternal immune activation (Figure 3).  
 
 
Figure 3. Steps of human brain development from gestation to adult life. Modified from Knuesel et al. 
2014. 
 
 
Thus, MIA animal models represent a very suitable tool to investigate the impact of 
infection exposure at different gestational stages on fetal neurodevelopment. This 
can be easily achieved by exposing pregnant animals to the infectious stimulus at 
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different times during pregnancy. Because the effects of compounds such as Poly I:C 
are time-limited (24-48 h depending on the dosage), it results quite easy to 
investigate the impact of MIA on a specific period of fetal development. Indeed, the 
gestational stage at which MIA is induced is crucial for the pathological outcome in 
the offspring; since each gestational period correspond to specific processes 
involved in the maturation of the CNS. Some anomalous response to classic 
conditioning protocols such as prepulse inhibition and latent inhibition are 
associated with schizophrenia and occur usually after the exposure to Poly I:C at 
gestational day 9, that correspond to the first trimester in women. Instead, defects 
in cognitive flexibility are more common in subjects exposed to MIA later, during the 
third trimester of pregnancy [30, 53]. 
 
Acute and long-term effects of prenatal immune activation on fetal brain 
Cytokine expression in the fetal brain 
It seems no longer a matter of debate that MIA is able to trigger unequivocal 
inflammatory responses in the mother that could influence fetal CNS development. 
However, which component of the acute inflammatory response might be required 
as mediator of MIA remains an open question. Is an alteration in a specific maternal 
cytokine, or other inflammatory mediators, fever, etc. necessary to produce effects 
on the fetal brain? It has been demonstrated that the administration of Poly I:C or 
LPS to pregnant rodents can clearly increase maternal levels of serum cytokines, 
including IL-1β, IL-6 and TNFα, and produce fever [30, 54-56]. Moreover, not only 
the production of pro-inflammatory compounds in the maternal compartment but 
also changes in cytokines and other mediators at the maternal-fetal interface (the 
placenta) could be possible mediators MIA-induced changes in fetal brain 
development and functioning later in life. Inflammation-induced alterations of the 
placenta may have detrimental consequences on fetal brain development, because 
increased levels of inflammatory cytokines, such as IL-6 and TNFα, in the placenta, 
have been implicated in placental dysfunction and trophoblast apoptosis [57-59].  
Of course, investigating acute neurochemical changes in the fetal brain results very 
important in understanding mechanisms mediating long-term changes in the 
offspring CNS following MIA. One of the most studied parameter in fetuses is 
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cytokine expression in the fetal brain. Indeed, altered mRNA levels for IL-6, IL-1β 
and TNFα, the main cytokines involved in the maternal immune response following 
Poly I:C or LPS administration, were found in fetal brains few hours after MIA 
challenge [30, 60]. Interestingly, IL-6, which is increased in maternal serum, 
amniotic fluid, placental tissue and fetal brain, can induced MIA by itself, leading to 
the same behavioural abnormalities observed upon viral infections, Poly I:C or LPS 
[61]. Moreover, the combined administration of IL-6 neutralizing antibody and Poly 
I:C in pregnant dams, prevents behavioural abnormalities and normalizes brain 
gene expression variations observed upon MIA challenge. Interestingly, IL-6 KO 
mice challenged with MIA do not display behavioural changes typically observed in 
MIA offspring [61]. Although lots of studies on MIA animal models provide evidence 
that MIA could trigger changes in cytokine profile in the fetus, more research needs 
to be done to explain how these changes are linked to MIA neuropathologies and 
how cytokines might affect fetal brain development. The ultimate challenge it would 
be to identify specific immune signatures related to specific disease-related 
neurodevelopmental and behavioural alterations.  
 
Synaptic development and neurotransmission 
Cytokines are known to regulate the expression of other immune molecules in the 
brain, including MHC class 1 molecules [40]. In the immune system MHCI is 
regulated by cytokines at the very early steps of the immune response while in 
healthy brains MHCI negatively regulates synapse formation and synaptic plasticity 
during their initial establishment in neurons [62, 63]. Indeed, alterations in synapse 
formation and synaptic pruning are associated with a range of neurodevelopmental 
diseases and are increasingly thought to be involved in the etiology of schizophrenia 
and ASD [64, 65]. MIA is able to determine a dramatic change in MHCI levels in 
neurons in the new-born offspring [66], and this seems to be involved in the MIA-
induced defective ability of newly born neurons to form synapses and to create the 
correct connectivity. In fact, neurons from rats exposed to MIA present increased 
levels of MHCI accompanied by a reduced number of synapses and an impaired 
neural connectivity [67]. Since MHCI is able to mediate responses to infection in 
neurons and simultaneously to regulate the activity-dependent plasticity and the 
circuit formation, these findings support the idea that deregulated MHCI proteins 
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may mediate synaptic dysfunctions and cognitive impairments, although studies on 
this topic have to be strongly improved. 
 
Transcriptional and epigenetic modification following MIA 
Fatemi et al., in 2005, were the first to describe transcriptional alterations in 
neonatal brains upon viral infection in a mouse model of MIA. These alterations 
primarily affect genes involved in basic cell functions. In particular, they showed the 
upregulation of 21 genes and downregulation of 18 genes in the affected neonatal 
brain, including cytosolic chaperone system, HSC70, bicaudal-D, aquaporin 4, 
carbonic anhydrase 3, glycine receptor, norepinephrine transporter and myelin 
basic protein. For the first time they demonstrated that prenatal human influenza 
infection at GD9 leads to alterations in a subset of genes in the brain of exposed 
offspring, potentially leading to permanent changes in brain structure and functions 
[68]. A great history of studies has focused on early life programming as a source of 
adult mental illnesses; older theories have been increasingly replaced by new ones 
considering complex interactions between genes and environment. Thanks to these 
studies, it has recently become clear that early life experiences, like infections, 
maternal care, nutrition and stress, are able to program the brain in order to confer 
vulnerability or resilience and this process seems to involve epigenetic mechanisms, 
including DNA methylation, histone modifications and the actions of small non-
coding RNAs, regulating the expression of individual genes or large gene clusters 
[69]. Several lines of evidence indicate that the timing of the exposure to an 
environmental risk factor may determine whether the event has limited and specific 
epigenetic effects or whether it affects the epigenome in a more extended way, as 
well as how long the effect persists [52]. As epigenetic processes are an integral part 
of the neurodevelopmental maturation, insults that are experienced during key 
periods roughly corresponding to early or late gestation, could be involved in 
reprograming the epigenome more extensively also through generations, even if 
incorporated into the germ cells [69] (Figure 4). 
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Figure 4. Modes of maternal and paternal transgenerational epigenetic transmission. In germline, 
epigenetic inheritance, an environmental effect occurring during development results in an epigenetic 
change within the first filial generation (F1) offspring’s germ line that is transmitted to F2 offspring, F3 
offspring, and so on. Modified from Bale et al. 2015 and Danchin et al 2011 
 
 
Remarkably, pro-inflammatory cytokines produced by the mother upon MIA may 
affect fetal somatic cells interacting with the epigenetic machinery. Indeed, the 
expression of DNA(cytosine5)-methyltransferase 1 is increased by IL-6 which can 
regulate its promoter [70]. Tang et al., in 2013, detected strong deficits in the 
expression of genes associated with immune signalling, neuronal development and 
synaptic transmission in the cortex of juvenile Poly I:C-exposed mice. In particular, 
they found several genes in the glutamate receptor signalling pathway, including 
Gria1 and Slc17a7, showing decreased histone acetylation in a promoter-specific 
way, corresponding to a defective gene expression. In contrast, the expression of 
these same genes, including also Disc1 and Ntrk3, was increased in the hippocampus 
of juvenile mice, according with elevated levels of promoter-specific histone 
acetylation. These results suggested to the authors that early epigenetic changes 
could contribute to the behavioural abnormalities observed in adult animals, 
comparable with the symptoms observed in schizophrenia and related disorders 
[71]. The alteration of neurodevelopmental mechanisms by abnormal expression of 
these genes may act synergistically with prenatal inflammation to increase the risk 
of long-lasting neurodevelopmental brain disorders. This scenario would be 
consistent with the hypothesis that the interaction between environmental and 
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genetic factors play a fundamental role in the etiology of major neuropsychiatric 
disorders such as schizophrenia and autism [72, 73].  
An important target for epigenetic modifications in models of neurodevelopment is 
represented by MeCP2 (Methyl CpG-binding protein2) [74]. MeCP2 works as a 
transcriptional repressor or activator with a very precise timing, by recruiting 
transcription factor CREB1 (cAMP responsive element-binding protein 1), 
depending on the methylation status of the DNA [75]. In the brain, it is abundant in 
neurons and it’s associated with the maturation of the CNS and in the formation of 
synaptic contacts [76]. MECP2 has a well-established role in Rett syndrome but has 
also been implied in neurodevelopmental disorders such as autism and 
schizophrenia [77]. Aberrant promoter methylation of MECP2 itself is thought to 
contribute to defective biological processes and potentially to the etiology of 
neurodevelopmental disorders [78]. In a paper from Basil and colleagues published 
in 2014, it is reported an association between MIA, induced by Poly I:C injection at 
GD9, and MeCP2 promoter hypomethylation [74]. Since Poly I:C is known to 
determine an increase in IL6 and MeCP2 in turn may suppress IL6 expression [79], 
they speculate that hypomethylation of MeCP2 promoter, that leads to higher levels 
of MeCP2, may be involved in silencing genes that are activated by the immune 
response. As previously described, changes in MeCP2 could influence the expression 
of other genes involved in neurodevelopment, already reported to be altered in the 
MIA models; for example, BDNF (brain-derived neurotrophic factor) [80], reelin and 
glutamate decarboxylase 67 [81], CREB1 [82] and histone deacetylases and DNA 
(cytosine-5)-methyltransferase 1 [83].  
 
Behavioural changes in the MIA offspring 
The most frequently altered behavioural feature in the offspring after prenatal 
immune activation is the prepulse inhibition (PPI); a neurological phenomenon in 
which a weak pre-stimulus (prepulse) is able to inhibit the reaction of the subject to 
a second strongest, sudden and startling stimulus (pulse), administered soon after 
the prepulse stimulus. The stimuli usually used are acoustic, but also tactile or light 
stimuli can be used. The startle reflex (startle response) is the response to a sudden 
and relatively intense stimulus, which is manifested by a contraction of skeletal and 
facial muscles, usually classified as a defensive reaction. The prepulse inhibition 
20 
 
paradigm consists in the normal suppression of the startle reflex occurring when an 
intense stimulus (pulse), able to evoke the startle reflex itself, is preceded by a 
weaker sensory event, the prepulse. The degree by which the prepulse stimulus 
inhibits the motor response to the pulse stimulus, constitutes one of the simplest 
measures of the sensorimotor inhibition, or "sensorimotor gating". 
To date, the PPI constitutes the most powerful tool for studying not only the 
modulation of reflexes, but also the sensorimotor gating deficits associated with 
psychiatric disorders, such as Tourette's syndrome and schizophrenia. One of the 
major advantages of using this method is represented by the fact that homologous 
behavioural phenomena can be studied in different species. In humans, the startle 
reflex is measured with an electromyographic examination of orbicularis oculi 
muscles (eyeblink), while in rodents a stabilometric force platform is used to 
measure the stress induced by the startle stimulus. 
Deficits in the PPI were found in animal models on MIA following the prenatal 
administration of either Poly I: C and LPS [84, 85]. Several working groups have 
pointed out defects in PPI after administration of Poly I: C in early-mid gestation 
(GD9-GD12.5) [51]. For example, Meyer and colleagues identified defects in the PPI 
after administration of Poly I: C at GD9 but not at GD17 [86], supporting the 
hypothesis that the central period of pregnancy in mice represent a critical window 
of sensitivity to Poly I: C stimuli. Moreover, latent inhibition, exploration in the open 
filed, spatial working memory evaluated in the Morris water maze and social 
interactions were found altered in Poly I:C prenatally treated mice (GD12.5/GD17) 
[30, 61, 86]. Defects in the PPI, latent inhibition and spatial learning in the Morris 
water maze have also been observed in mice following the administration of 
influenza virus and IL-6 [26, 61, 87].  
In addition, altered spatial learning was observed following LPS injection at GD19, 
evaluated through Morris water maze test, while no spatial learning impairment 
were reported in mice exposed to LPS at GD17 [88]. As for defects in memory, Golan 
and colleagues demonstrated that mice born after prenatal injection of LPS at GD17 
prefer the new object respect to the known object in the novel object recognition 
test (NORT) compared to the control mice [89]. The NORT is used to evaluate 
cognition, particularly the recognition memory, in rodent models of CNS disorders. 
This test is based on the physiological and spontaneous tendency of rodents to 
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spend more time exploring new objects compared to familiar objects. The choice to 
spend more time exploring a new object reflects the capability of the animal to use 
learning and recognition memory skills. Offspring born after prenatal treatment 
with LPS at GD9 show a greater interest in the familiar objects respect  to the new 
one [90], in contrast to what was observed following injection at GD17 [89]. These 
differences suggest that mice born after LPS injection in the mother do not have 
deficits in discriminating between familiar objects or new but instead show different 
preferences according to the period in which the LPS administration takes place. 
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Chapter 2 
 
THE ROLE OF INFLAMMATION IN EPILEPSY 
 
Medical classification and symptoms of epilepsy 
The term “epilepsy” includes a set of heterogeneous neurological disorders 
characterized by recurrent epileptic seizures. These seizures are caused by an 
abnormal synchronous firing of groups of neurons (hyper-synchronization), from 
which derives a periodic neuronal hyper-excitability. Seizures represent the most 
frequent neurological event in childhood and are characterized by sudden and 
involuntary alterations in the brain functions, secondary to abnormal neuronal 
discharges. 
As mentioned above, there are many types of epilepsy and equally varied are the 
ways in which the disease is manifested. An epileptic patient is a person who has 
experienced at least two unprovoked seizures at a distance of at least 24 hours; since 
seizures can occur also because of fever, infections of the nervous system, acute 
trauma or upon fluctuations of electrolytes levels in the blood. 
 
Etiology 
Worldwide, about 1% of people is affected by epilepsy, and nearly 4% will 
experience epilepsy at some point during their lifetime. 75% of people with epilepsy 
are affected within the first 20 years of life and the incidence in children is around 
50 new cases every 100000 children, with an increasing rate during the first year of 
life. Epilepsy seems to affect equally both sexes and persons belonging to different 
ethnic groups, with a homogeneous geographical distribution. 
Although the majority of patients can benefit from effective pharmacological or 
surgical treatments, approximately 30% of patients do not respond to the canonical 
therapies [91] . To date, over 50% of epilepsy cases are considered idiopathic, or 
primary, without a clear etiology. In the remaining cases, called secondary 
syndromes or symptomatic, the disease may be related to genetic factors, 
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neurodevelopmental defects, infections, trauma, stroke or brain tumours. These 
events can lead to the pathology with latency periods up to 10 years [92]. 
Based on EEG recordings, epileptic seizures can be classified as partial or 
generalized [93]. Partial seizures, also called focal seizures, originate from a specific 
brain area and we can distinguish three different types: 
- Simple, characterized by a minimum spread of the discharge, so that 
consciousness and awareness are maintained (10%); 
- Complex, starting with a localized attack, in which, however, the discharge 
is more widespread (generally bilateral); almost every time they involve the 
limbic system and are characterized by loss of consciousness (35%); 
- Secondarily generalized, partial seizures immediately preceding a tonic-
clonic generalized seizure. 
 
On the other hand, generalized seizures usually involve both cerebral hemispheres, 
and are divided into: 
- Tonic-clonic seizures, or grand mal (30%), which are the most dramatic 
ones characterized by hypertonia of all body ends followed, after 15-30 
seconds, by tremor, which represents the interruption of the tone and finally 
by relaxation; 
- Absences, characterized by a sudden attack that stops just as suddenly (from 
4 to 20 seconds), in which there is an alteration of consciousness. They are 
also called "Petit mal" because they represent one of the most typical forms 
of child and juvenile epilepsy [94], involving learning deficits. The distinctive 
electroencephalographic signs of typical absences are represented by 
complex spike-wave discharges (SWDs) at 3-4 Hz: regular and symmetrical 
generalized discharges with normal background rhythm, occurring in the 
thalamocortical circuits [95]. 
- Myoclonic seizures (4%), characterized by myoclonic jerks, usually caused 
by sudden involuntary contractions of a muscle or a group of muscles, loss of 
muscle tone and fall; 
- Atonic seizures, due to loss of postural tone; if standing the patient suddenly 
falls to the ground, if sitting the torso and the head can fall forward. 
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Contribution of inflammation to epilepsy 
The CNS is considered a privileged system from the point of view of immunity. In 
fact, the presence of the blood brain barrier (BBB) protects the brain from 
inflammatory insults. However, it is well established that immunological and 
inflammatory reactions can occur in the CNS despite the presence of the BBB, 
because they can occur also intrinsically, constituting a direct part of the innate 
immunity. Inflammation in the brain is a condition characterized by the presence of 
a series of molecules, cytokines – soluble polypeptides acting as inflammatory 
mediators - and other inflammatory molecules, which are almost undetectable 
under physiological conditions [96]. Classically, these molecules are produced by 
cells of the immune system; however, it is known that the brain parenchymal cells, 
astrocytes, microglia and neurons as well as the choroid plexus and the BBB cells 
can produce these inflammatory mediators. Experimental evidence indicates a 
dichotomous role of immune responses in the CNS; these reactions can be both 
protective as well as directly or indirectly involved in neuronal dysfunctions [97]. 
Molecules produced both by the innate and by adaptive immune systems are 
induced in a great number of different neurological disorders, including Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis and 
amyotrophic lateral sclerosis (ALS). In Alzheimer's disease, a robust inflammatory 
response of the brain is associated with the deposit of extracellular β-amyloid 
protein, involved in neurodegeneration. However, a beneficial effect of the 
inflammatory response in the pathology is highlighted by recent evidence that the 
activation of microglial cells and the production of transforming growth factor β1 
(TGF-β1), can participate in the elimination of deposits of β-amyloid protein, 
thereby preventing their harmful effects [98]. In addition, peripheral antibodies 
against specific neuronal targets can be produced in rare inflammatory neurological 
disease including stiff-man syndrome, Rasmussen’s encephalitis (RE) and 
paraneoplastic neurological diseases, causing neuronal dysfunctions and cell death 
by targeting specific antigens [99]. Moreover, inflammatory response play an 
important role also in acute CNS injury, like stroke and cerebral ischemia, brain 
trauma as well as in epilepsy.  
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Effects of pro-inflammatory cytokines on seizures 
Increasing evidence implicates proinflammatory cytokines as neurochemical 
mechanism underlying epilepsy [100]. An inflammatory response in the CNS can 
trigger seizures and epilepsy, while pro-inflammatory cytokines such as IL-1, TNFα 
and IL-6 are increased by seizure activity determining a vicious cycle between brain 
inflammation and epilepsy. Cytokines can directly affect neuronal excitability acting 
on ionic currents and indirectly by acting on gene expression in glial cells and 
neurons. Exogenous administration of IL-1β previous to chemically induced 
seizures by intracerebral application of kainic acid or bicuculline methiodide is able 
to enhance and prolong seizures in rat models [101], whereas the specific antagonist 
IL-1Ra, injected intracerebrally, is able to reduce seizure susceptibility [102]. These 
data are strengthened by the evidence that inhibiting the production of IL-1β  by 
using selective blockers or gene knockout for caspase-1, the enzyme involved in the 
production of the active form of IL-1β, significantly reduces seizures [103]. For what 
concerns another important pro-inflammatory cytokine, IL-6, it has been 
demonstrated that IL-6 levels are increased after seizures, although IL-6 KO mice 
are more susceptible to seizures than WT mice [104], suggesting a protective role 
for this cytokine. However, the use of transgenic mice overexpressing IL-6 in 
astrocytes, indicate an increased sensitivity to seizures induced by glutamatergic 
agonists [105]. Moreover, also cytokines produced after febrile events have been 
closely linked to epilepsy, in particular to childhood epilepsies. Several pro-
inflammatory cytokines, including IL-1β, act as pyrogens when centrally or 
systemically administered. Intracerebroventricular injection of IL-1β  is able to 
reduce the threshold for seizures in 14 days old mice subjected to hyperthermia and  
in 14 days old rats exposed to LPS-induced fever [106, 107]. Moreover, IL-1β 
receptor-deficient mice or IL-1Ra-injected rats resulted resistant to this type of 
seizure induction. All together these data suggest that IL-1β  signalling displays pro-
convulsive properties, although anticonvulsive effects this cytokine have been 
demonstrated in few works [108, 109]. 
Also systemic infections seem to play an important role in seizure susceptibility. For 
example, infections caused by the Enterobacter Shigella dysenteriae in mice 
significantly increases seizure susceptibility upon Pentylenetetrazole 
administration and IL-1β  and TNFα seem to play an important role in CNS 
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sensitization to infection-induced seizures, because systemic pre-administration of 
antibodies against these two cytokines in the infected animals is able to prevent the 
increase in seizure susceptibility [110, 111]. 
 
MIA and epilepsy 
As mentioned above for schizophrenia and autism spectrum disorders, also in 
epilepsy the prevalence of the pathology in subjects exposed to inflammatory 
stimuli during the mother's gestational period is significantly increased; considering 
also the 20-46% of children with autism spectrum syndromes which display 
sporadic epileptic episodes in adult life [112]. Moreover, the prevalence of epilepsy 
is significantly increased also in the so called “winter babies” [113]. Furthermore, a 
recent population-based cohort study conducted by Sun and colleagues and based 
on data from the Danish National Birth Cohort (1996-2002), demonstrated an 
association between maternal infection, accompanied by febrile episodes during 
pregnancy and childhood epilepsy [114]. This and other epidemiological studies 
showed that maternal cystitis, vaginal yeast infections, coughs and other disorders 
accompanied by maternal fever are associated with an increased risk for epilepsy in 
the offspring. A similar epidemiological study, carried out by Nørgaard and 
colleagues in 2012, on children born between 1998 and 2008 in northern Denmark, 
showed a 40% increase in the risk of developing epilepsy after prenatal maternal 
infections [115]. In the work of Nørgaard it was not found any association between 
the disease and treatment with antifungal, while Sun and colleagues demonstrated 
an association between vaginal yeast infections and an increased risk of developing 
epilepsy in the offspring [114]. Children born after prenatal exposure to more than 
two episodes of fever maternal, with urinary symptoms or with temperatures of 
39.0 ° C or more, showed increased risk of developing epilepsy, suggesting that the 
causes of the fever, rather than the high temperature, to have a role in the onset of 
pathology [116]. Recently, pre-clinical evidence demonstrated that MIA, through 
Poly I:C immune activation, is able to increase seizure susceptibility [117] and 
hippocampal excitability [118]. 
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Chapter 3 
 
THE EXCITATORY/INHIBITORY BALANCE: IMPLICATIONS FOR 
NEUROPSYCHIATRIC DISORDERS 
 
In the context of neurophysiology, the development of correct brain functions 
depends upon the maintenance of several balances including cell growth/cell 
proliferation, oxidant/anti-oxidant equilibrium, neurotransmitter release, pro- and 
anti-inflammatory molecules. Among these balances another important one is 
represented by excitation and inhibition balance (E/I balance), that refers to the 
relative contributions of excitatory and inhibitory synaptic inputs responsible for 
correct transmission, circuit formation, cortical layer organization and neuronal 
plasticity [119-121]. Deregulation of the E/I balance has been associated with a 
variety of human neurodevelopmental disorders characterized by cognitive and 
social deficits, including autism and schizophrenia [122, 123]. 
In the cerebral cortex, neuronal circuits are constituted by two main classes of 
neurons: excitatory neurons, mainly using glutamate as neurotransmitter, and 
inhibitory interneurons, that represent about 20-30% of all cortical neurons, using 
γ-aminobutyric acid (GABA) as neurotransmitter [124]. Cortical GABAergic 
interneurons have been shown to play a vital role in controlling the function of 
cortical networks, in modulating neuronal excitability and integration, in the 
generation of temporal synchrony and thus oscillation among glutamatergic circuits 
[125-127]. GABAergic interneurons are also crucial in the regulation of all of the key 
steps during neurodevelopmental in the cortex, form neuronal proliferation, 
migration and differentiation to experience-dependent organization and plasticity 
of local cortical circuits [128, 129]. Thus, not surprisingly, aberrant development of 
GABAergic transmission has been related to many neurodevelopmental disorders 
including schizophrenia, autism, Rett syndrome, Down syndrome as well as 
developmental epilepsy [124, 130, 131].  
The formation of the GABAergic network can be divided into distinct developmental 
steps (Figure 5): generation of specific GABAergic subtypes, migration in the 
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appropriate brain region, cell axon growth towards specific post-synaptic targets and 
finally the use-dependent adjustment of GABAergic synapse number and strength.  
 
 
 
 
Figure 5. Time course of GABAergic circuit development. The development of GABAergic circuits is a 
long process starting during mid-gestation and completed only by the end of adolescence. In the 
immature brain, GABA-releasing synapses are formed before glutamatergic contacts in a wide range of 
species and structures and therefore represent the first form of communication between neurons. Early 
on, GABA action is excitatory and becomes later inhibitory because of the delayed expression of a 
chloride transporter, leading to a negative shift in the reversal potential for Cl-. 
 
 
Moreover, a striking characteristic of GABAergic interneurons is the exuberance of 
their innervation field. In rodents and in primates, this rich pattern of innervation is 
not completed before late adolescence. This time window, during which experience 
can sculpt GABAergic network architecture, is fundamental. Indeed, sensory 
deprivation during this critical post-natal period deeply retards GABAergic 
synapses maturation in visual and somatosensory cortex [132, 133]. The first 
molecule involved in this process is Brain-derived neurotrophic factor (BDNF) that 
promotes the formation of GABAergic synapses in hippocampal and cortical cell 
cultures [134]. More recently, it has been demonstrated that GABA signaling itself 
can promote GABAergic maturation and innervation in the adolescent cortex [135]. 
Therefore, dysregulations in one of the crucial stages of GABAergic network 
development and maturation could lead to an aberrant function of cortical circuits 
resulting in the manifestation of a pathological phenotype. 
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Cation-chloride cotransporters involvement in E/I balance 
Another fundamental process involved in the correct developing of GABAergic 
circuit and in the maintenance of a proper E/I balance is represented by the “GABA 
switch”; a process in which GABAergic signalling shifts from depolarization to 
hyperpolarization through development.  
Electrical activity in neurons needs a functional and synergic coupling between ion 
channels and ion transporters. It has become increasingly evident that one family of 
ion transporters particularly, the cation-chloride cotransporters (CCCs), play a 
fundamental role in shaping the GABAergic signalling and neuronal connectivity 
[136]. Although GABA is known to be the main inhibitory neurotransmitter in the 
adult brain, during embryonic neurodevelopment it can depolarize neuronal cell 
membranes depending on the Cl– gradient across them. Indeed, in brain structures 
such as the hippocampus, the neocortex and the hypothalamus, the inhibitory 
properties of GABA only emerge after birth [137].  
Two members of the SLC12 family, a solute carrier family of electroneutral CCCs, 
NKCC1 (Na+-k+-2Cl- cotransporter 1) and KCC2 (K+-Cl- cotransporter 2), are known 
to have cell-autonomous functions in the CNS; they play an important role in setting 
the reversal potential and the driving force of the anion currents mediated by 
GABAARs, as well as glycine receptors [138] and non-ligand-gated Cl- channels [139, 
140]. During the GABA switch the lowering of the resting intracellular chloride 
concentration is mediated by a progressive downregulation of NKCC1 (chloride 
importer) and upregulation of KCC2 (chloride extruder) (Figure 6) [141-143].  
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Figure 6. (A) Schematic diagram of the alterations in [Cl−]i in immature and mature neurons. In 
immature neurons NKCC1 expression is high while KCC2 is low, resulting in high [Cl−]i. In the normal 
mature nervous system, the situation is reversed; expression of NKCC1 is low and that of KCC2 is high, 
resulting in low [Cl−]i. (B) Line plots showing the average exon array signal intensity of cation-chloride 
cotransporter (CCC) transcripts in the human neocortex from the early fetal period to late adulthood. 
Modified from Ben-Ari 2015 and Kaila et al. 2014.  
 
 
This shift has been observed in a large number of different animal species and brain 
regions, suggesting that it has been conserved throughout evolution [144]. 
Interestingly, this developmental decrease in intracellular [Cl-] does not occur in 
other cellular types, stressing the point that immature neurons, where intracellular 
[Cl-] is higher, are not an exception as usually thought by neurobiologists, but rather 
are mature neurons to be an exception respect to other cell types. Chloride is used 
by cells to maintain basic cellular parameters such as cell volume and intracellular 
pH and there is a high metabolic cost associated with the maintenance of low 
intracellular chloride concentrations and generation of hyperpolarizing currents. 
Thus, the frequently reported downregulation in KCC2 expression, upon neuronal 
trauma may be a consequence of an adaptive mechanism put in place by neurons to 
survive by reducing energetic costs [145, 146]. 
 
CCCs in seizures and epilepsy 
Much of the neurobiological research on seizures and epilepsy has gravitated 
towards the role of synaptic transmission, especially GABAergic transmission, 
 [Cl-] [Cl-] 
A       B 
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because of its crucial role in maintaining the balance between excitation and 
inhibition (E/I). With the identification of the molecular mechanisms of synaptic 
transmission, it has become even clearer that defects in almost every step of 
synaptic transmission can lead to the onset of seizures. Particularly interesting is 
the role of ion transporters which, as mentioned above, affect the reversal potential 
of GABAAR-mediated currents (EGABA), in what is called “ionic plasticity”. GABAergic 
signalling has the unique property of “ionic plasticity”, which is based on short-term 
and long-term changes in the Cl− and HCO3− ion concentrations in the postsynaptic 
neurons. While short-term ionic plasticity is caused by activity-dependent, channel-
mediated anion shifts, long-term ionic plasticity depends on changes in the 
expression and kinetic of molecules involved in anion homeostasis [147]. 
Accumulating evidence suggests that this high plastic ion regulation in neurons, 
contributes to the multiple roles ascribed to GABAergic signalling during 
epileptogenesis and epilepsy [146].  
It has been demonstrated that mice, in which the gene encoding for KCC2 is 
disrupted, show frequent generalized seizures and die shortly after birth. The most 
affected regions are the hippocampus, temporal and entorhinal cortices. Moreover, 
adult heterozygous animals, which are vital, show increased susceptibility to 
epileptic seizure, thus indicating that KCC2 plays an important role in controlling 
CNS excitability during both postnatal development and adult life [148]. In addition, 
progressive downregulation of KCC2 after pilocarpine-induced status epilepticus 
decreased the inhibition efficacy and abolished the capacity of the dentate gyrus to 
work as a hippocampal barrier against seizure activity arising in the entorhinal 
cortex. Indeed, in normal adult dentate granule cells in rats, spiking of these cells is 
strongly suppressed by KCC2-dependent GABAergic signalling. [149].  
Temporal lobe epilepsy (TLE) is the most common type of refractory epilepsy in 
humans. The primary cause leading to TLE is typically a brain insult, such as 
traumatic brain injury, inflammation or status epilepticus, but in patients the nature 
of the initial insult remains often unknown because of the long delays between the 
insult and the appearance of recurrent seizures [150]. It has been observed that in 
hippocampal brain slices from adult patients with TLE, downregulation of KCC2 and 
upregulation of NKCC1 leads to depolarizing GABAAR responses in a subpopulation 
of subicular principal neurons. This has been implicated in the generation of 
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spontaneous interictal-like (but not ictal-like) activity [151-153]. What was 
interestingly found is that by inhibiting NKCC1, using diuretic bumetanide, that at 
low concentration almost specifically inhibits NKCC1 without significantly affect 
KCC2, it is possible to block interictal activity in vitro [152]. Moreover, patients with 
TLE showing depolarizing GABAergic neurons in the subicular pyramidal cells as 
well as increased NKCC1 mRNA levels in the hippocampus [154],  show a decreased 
depolarizing activity of GABA upon treatment with bumetanide [152].  
Recently, a rare point mutation (KCC2-R952H) in the SLC12A5 gene (the gene 
encoding for KCC2) was identified in an Australian family with early childhood onset 
of febrile seizures [155]. This missense mutation led to defects in neuronal Cl− 
extrusion capacity as well as defects in cortical dendritic spine formation in rodent 
neurons, suggesting that this variant represent a good candidate for febrile seizures 
susceptibility [155]. Support for this conclusion was gained from another point vari-
ant, the KCC2-R1049H, found in a French-Canadian cohort with idiopathic 
generalized epilepsy [156].  
Thus, GABAAR signalling appears to resume its immature, depolarizing activity at 
least in some pyramidal neurons during epileptogenesis. 
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AIM OF THE STUDY 
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The developing brain is highly sensitive to several environmental insults, such as 
maternal stress and nutritional deficiencies, that can induce damaging effects in the 
future child [1]. Among these insults, infection-induced maternal immune activation 
(MIA) during pregnancy represent one of the most dangerous. In fact, MIA can 
contribute to the onset of causal chains of events leading to several 
pathophysiological changes in the fetal environment and contributing to postnatal 
brain dysfunctions. Several epidemiological studies confirmed that infections 
occurring during pregnancy, caused by different pathogenic agents, are associated 
with an increased incidence of neurodevelopmental disorders in the offspring, such 
as autism and schizophrenia. As for these two neurodevelopmental disorders, the 
prevalence of epilepsy is significantly increased in the “winter babies” [113]. 
Furthermore, a recent population-based cohort study demonstrated an association 
between maternal infections, accompanied by febrile episodes during pregnancy 
and childhood epilepsy [114]. This and other epidemiological studies showed that 
maternal cystitis, vaginal yeast infections, coughs and other diseases accompanied 
by maternal fever are associated with an increased risk for seizures and epilepsy in 
the offspring.  
It has been recently demonstrated in animal models that prolonged prenatal 
exposure to Poly I:C (polyinosinic:polycytidylic acid),  a viral mimetic, leads to 
increased hippocampal excitability, faster progression of kindled seizures and 
prolonged persistence of the kindling state, along with impaired social interactions, 
requiring the activation of both IL-6 and IL-1β [117]. However, the mechanisms 
directly involved in the increased excitability following prenatal inflammation have 
not been clarified yet.  
The aim of my PhD project was therefore to assess the effects of a single immune 
challenge, at early stages of gestation, on the susceptibility to epilepsy in the 
offspring, with particular interest to the mechanisms and the pathways involved. To 
this purpose, we developed a mouse model of MIA, consisting in a single injection of 
the immunogenic agent Poly I: C at gestational day 9 (GD9), corresponding to the 
first trimester of pregnancy in humans. Offspring was than subjected to behavioural 
analysis, while tissues collected at different times of embryonic development and 
from young and adult animals were used for functional, biochemical and molecular 
analyses in order to investigate the mechanism underlying the altered susceptibility 
35 
 
to seizures observed in adult Poly I:C offspring. The data presented in this thesis and 
future experiments will contribute to better understand the link between prenatal 
inflammation and epilepsy and to elucidate the molecular mechanisms that may 
contribute to the development of seizures following maternal immune activation. 
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CHOICE OF THE MIA MODEL: INTRAPERITONEAL POLY I:C 
INJECTION AT GESTATIONAL DAY 9 
 
The first part of this study consisted in setting up the optimal experimental 
conditions and the proper timing to investigate the pathological effects induced by 
MIA. Given the extensive literature concerning MIA models, in which a wide variety 
of substances, doses and times are applied, a real established and accepted model of 
MIA is still lacking. Nevertheless, in order to mimic a mild pathological infection in 
the mother, in which animals did not manifest any signs of physical discomfort, we 
decided to induce MIA by intraperitoneal injections of 2 mg/kg Poly I:C: 40% of the 
amount commonly used in literature [30, 34, 51]. Poly I:C was injected at gestational 
day 9 (GD9), corresponding to the end of the first trimester of human pregnancy in 
terms of fetal development and percentage of pregnancy total duration [157]. This 
temporal window of embryonic development was chosen because it is believed to 
constitute a critical window of susceptibility to inflammatory events [85, 158]. The 
analyses were then carried out both during embryonic stages (3-6-24 hours post-
injection and E17) as well as during postnatal adult life (P20 and P90). As mentioned 
above, many neurodevelopmental disorders manifest the first clinical symptoms in 
post-pubertal age, having a greater impact on adult life [159, 160]. Therefore, these 
times allowed us to investigate the events in the offspring following the maternal 
inflammatory insult till the onset of the disease. We decided to use only male 
offspring because of the absence of the hormonal cycle, which could introduce 
different variables difficult to manage, in particular for what concerns behavioural 
tests but also biochemical analyses. Furthermore, it is also known that both at 
anatomical and functional levels the brain is deeply influenced by gender and by the 
action of steroid [161]. In addition, data regarding the prevalence of neurological 
and psychiatric disorders in humans show a different vulnerability of the two sexes 
as well as a sexual dimorphism [162]. It was therefore necessary for this study to 
make a priori choice about the sex to be examined, even if it could be very interesting 
in the future to study females in order to investigate any possible difference in the 
two sexes upon MIA challenge. 
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VALIDATION OF THE MODEL 
 
Since it is known that prenatal Poly I:C administration at GD9 is able to increase IL-
6 blood levels in the mother 3 hours after the injection [30], we collected blood from 
3-6 months old females 3 hour after Poly I:C or vehicle injection, in order to compare 
our results with the literature, thus validating our model. The proinflammatory 
cytokine IL-6 is a multifunctional cytokine with a variety of implications in several 
pathological conditions. Physiologically its level is less than 1 pg/ml in human blood 
but it’s subjected to a rapid upregulation in pathophysiological conditions [163]. In 
our experimental model, 2 mg/kg Poly I:C were able to significantly increase IL-6 
plasmatic levels in treated pregnant mothers respect to control mice as detected by 
ELISA kit (Figure 1). This result is in line with those reported in literature [30, 164], 
thus confirming the validity of the chosen MIA model. 
 
 
 
Figure 1. IL-6 plasma levels in adult females detected by ELISA kit 3 hours after Poly I:C/vehicle ip. 
injection. Student’s t-test, **p=0,0014. Ctrl n=4; Poly I:C n=5. 
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SUSCEPTIBILITY TO KAINIC ACID-INDUCED SEIZURES IS 
INCREASED IN POLY I:C PRENATALLY-TREATED OFFSPRING 
 
Recently it has been demonstrated that increased susceptibility to seizures can be 
ascribed to inflammatory insults during prenatal life. In fact, the daily 
administration of Poly I:C in pregnant dams from GD12 to GD16, is able to increase 
seizure susceptibility in the offspring, examined using the rapid hippocampal 
kindling model [165]. We therefore aimed to investigate whether an earlier and 
single intrauterine exposure to Poly I:C, performed at the very beginning of the 
cortical neuronal layering (GD9), was sufficient to increase offspring susceptibility 
to seizures in adulthood. For this purpose, MIA offspring was examined at 3 months 
of age (P90) after ip. administration of 35 mg/kg kainic acid (KA), a potent agonist 
of a subtype of glutamate receptors capable of inducing seizures in a stereotyped 
way [166]. The mice were then observed and evaluated over a 3-hour period 
according to the Racine’s scale. Figure 2 shows that prenatally Poly I:C-treated mice 
are more susceptible to seizures induced by KA compared to control offspring.  
 
 
 
Figure 2. Evaluation of the behavioural response of control and Poly I:C prenatally-treated mice to 35 
mg/kg kainic acid injection (A) Time course of the behavioural response to 35 mg/kg injection of KA of 
control mice (n=9) vs Poly I:C mice (n=10). Two-way ANOVA followed by Sidak’s multiple comparisons 
test; *p<0,05, **p<0,01, ***p<0,001. (B) Mean score variation at the end of the experiment (180 
minutes). Student’s t-test, ***p=0,0004. 
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In all mice, KA was able to induce, within the first 10 minutes, immobility and 
staring, followed by head bobbing and isolated limbic motor seizures (stage 4 of 
Racine’s scale), characterized by forelimb clonus and rearing. Latency to the first 
stage 4 between Poly I:C and Ctrl mice was not statistically different in the two 
experimental groups even if, in general, Poly I:C mice reached stage 4 earlier than 
control mice. However, while control animals only displayed isolated limbic motor 
seizures, without reaching higher stages, Poly I:C mice rapidly progressed to stage 5 
(status epilepticus) and showed continuous generalized activity lasting for about 80 
minutes (Figure 2A). Thus, Poly I:C mice achieved significantly higher behavioural 
scores respect to control mice, starting from 60 minutes after KA injection and 
display a higher mortality rate: 28% vs 10%. Figure 2B shows the comparison 
between the Racine’s scores in the two experimental groups at the end of the 
experiment (180 minutes). Notably, no differences in the susceptibility to seizures 
were detected in dams (Figure 3A) and adult males (Figure 3B) treated with Poly I:C 
or vehicle during adulthood. All together, these data indicate that a single exposure 
to an infectious agent at GD9, is sufficient to increase susceptibility to seizures in the 
adult offspring.  
 
 
Figure 3. (A) Time course of the behavioural response to 35 mg/kg kainic acid injection of control and 
Poly I:C injected dams. Notably, there are no differences in the behavioural response between the 2 
experimental groups. Two-way ANOVA test. Ctrl n=6; Poly I:C n=10. (B) Mean score variation at the end 
of the 180 minutes observation in adult males who received vehicle or Poly I:C ip. in adult life. No 
differences were detected in the two experimental groups. Student’s t-test, Ctrl n=5; Poly I:C n=5. 
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POLY I:C INDUCES SHORT-TERM INFLAMMATORY RESPONSES IN 
THE EMBRYOS 
 
As already discussed previously, the MIA model consists in the activation of the 
maternal immune system during pregnancy following an inflammatory challenge. In 
order to verify whether the inflammatory stimulus we choose was able to induce, 
directly or indirectly, an immune response also in the embryos, we performed 
quantitative real-time PCR, for the main proinflammatory cytokines involved in 
MIA, directly in embryos. It is known that Poly I:C triggers immune responses 
through its binding with the specific Toll Like Receptor TLR3, which leads to the 
activation of different transcription factors, including CREB (cyclic AMP-responsive 
element-binding protein), AP1 (activator protein 1), NF-kB (nuclear factor-kB), 
IRF3 and IRF7 (interferon-regulatory factors), responsible for the production of 
several proinflammatory cytokines and interferon type 1 (Figure 4) [167, 168]. 
 
 
Figure 4. Intracellular TLR signalling pathways (Blasius et al. 2010).  
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To address this point, we analysed a panel of proinflammatory cytokines in embryos 
collected 3, 6 and 24 hours after Poly I:C treatment in the mother. Embryos were 
then analysed by means of quantitative real-time PCR. As reported in Figure 5, we 
observed a transient increase in the transcriptional profile of proinflammatory 
cytokines IL-6 (Figure 5A) and IL-1β (Figure 5B) 6 hours post-injection, while no 
statistical difference was observed 3 and 24 hours after the injection for IL-6. 
Interestingly, IL-1β was significantly reduced 24 h after the injection in Poly I:C 
offspring, possibly due to a compensatory mechanism. Unlike these cytokines, 
interferon β (IFNβ) showed no statistically significant variations at any of the 
analysed times (Figure 5C). The increase in IL-1β and IL-6 mRNAs levels indicates 
these immune molecules as the principal architects of the pathological phenotypes 
of MIA and suggests that our experimental procedure is able to activate not only the 
maternal immune system but also the embryonic one as a result of MIA. 
 
 
 
 
Figure 5. Cytokines mRNA levels in control and Poly I:C prenatally-treated embryos collected 3 (Ctrl 
n=6, Poly I:C n=5), 6 (Ctrl n=9, Poly I:C n=10) and 24 hours (Ctrl n=6, Poly I:C n=7) after the injection of 
Poly I:C/vehicle in the mother. (A) IL-6 mRNA levels are significantly increased 6 h post-injection in Poly 
I:C embryos. (B) IL-1β mRNA levels are significantly increased 6 h post-injection and significantly 
reduced 24 h after the injection in Poly I:C embryos. (C) Interferon β mRNA levels are not affected by 
MIA stimulus at any time after the immune challenge. Student’s t-test, *p<0,05, **p<0,01.  
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Although we found differences in timing between the inflammatory response 
observed in the mother (Figure 1) and that in embryos (Figure 5), we speculate that 
there could be a potential delay in the embryonic immune response due to the 
passage of the immune-stimulating agent through the placenta before reaching the 
fetal tissues. Moreover, the lack of increase of IFNβ argues in favour of a secondary 
activation of the embryonic immune system. Although different authors reported an 
increase of IL-1β, TNFα and IL-6 mRNA levels in rodent brains subjected to MIA at 
different developmental stages and upon different stimuli, there is currently no 
consensus on the extent of these variations [55, 169, 170]. Indeed, studies 
performed with Poly I:C at GD9, a paradigm similar to the one used in the present 
work, show conflicting data; Meyer and colleagues reported that this kind of 
treatment leads to a reduction of IL-1β mRNA levels 3 hours after the injection and 
an increase in IL-6 and TNFα levels [30]. It is possible that differences in the animal 
housing, in the mating timing and in the quality and quantity of the immune-
stimulating agent used may originate the observed differences. 
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INCREASED SUSCEPTIBILITY TO SEIZURES IN ADULT OFFSPRING 
DOES NOT REFLECT CHRONIC INFLAMMATORY PROCESSES IN THE 
BRAIN 
 
Given the increased seizure susceptibility in P90 animals and since it is well known 
that seizures and epilepsy may be the consequences of a chronic inflammatory 
status in the brain [171], we decided to investigated whether the increased 
susceptibility to seizures occurring in our model could be associated with an 
enhanced brain inflammation in adult life. Brains from P90 mice were examined by 
confocal microscopy in order to quantify the morphological appearance of 
microglial cells and the expression of proinflammatory markers.  
 
 
 
 
 
 
Figure 6. (A) Representative immunofluorescence images 
obtained from P90 cortical slices showing in green the specific 
microglial marker IBA1 and in red a marker for activated 
microglia, CD11b. Quantitative analysis of the total number of 
microglial cells (B) and of activated microglia (C). No significant 
differences were found between the two experimental groups. 
Student’s t-test.  
 
 
Figure 6B shows that the total number of microglial cells, revealed using the specific 
marker IBA1 is not altered in Poly I:C offspring respect to controls as well as the 
number of activated microglial cells, analysed by using the specific marker CD11b 
(Figure 6C). Moreover, GFAP (Glial fibrillary acidic protein), a marker for reactive 
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astrocytes, did not differ between the two experimental groups, analysed using 
western blotting technique (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Biochemical analysis of glial fibrillary acidic protein (GFAP) in the homogenates of adult 
(P90) Poly I:C prenatally-treated and control mice. (A) Quantitative analysis of GFAP protein levels 
showing no differences between the two experimental groups. Student’s t-test, Ctrl n=4, Poly I:C n=5. (B) 
Representative western blot lanes for GFAP and the housekeeping protein calnexin.  
 
 
A second parameter used to evaluate microglial activation concerns its ramification. 
Under physiological conditions microglia in the CNS exists in the ramified or what is 
generally termed ‘resting’ state. As appreciable in Figure 8A as well as in the 
quantification (Figure 8C), microglia from MIA offspring possess fewer branches 
respect to controls, while the length of branches does not change between the two 
experimental groups (Figure 8B).  
Consistently, quantitative real-time PCR performed for the two main cytokines 
already assessed in the embryonic age, IL-6 and IL-1β, did not reveal detectable 
mRNA levels both in Poly I:C and control mice brains (data not shown), indicating 
that the increase in proinflammatory cytokine levels during embryonic 
development is transient and does not produce any long term inflammatory 
condition in adulthood. 
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Figure 8. (A) Representative immunofluorescence images obtained from P90 cortical slices showing on 
the left the specific microglial marker IBA 1 (in green) and on the right the same image skeletonized for 
branches analyses. (B) Quantitative analysis of microglia branches length shows no differences between 
the two experimental groups. (C) Quantitative analysis of the number of microglial branches per cell 
shows a significant reduction in the number of microglial branches in Poly I:C offspring respect to 
controls. Student’s t-test, *p=0,0123. Ctrl n=3 animals, Poly I:C n=3 animals. 
 
 
Neuroinflammation is usually defined as an innate immune response which needs 
the contribution of glial cells for its propagation. Numerous studies have 
demonstrated that  inflammation is an important factor in determining neurological 
and psychiatric disorders, such as major depression, and drugs known for their anti-
depressant properties exhibit at the same time anti-inflammatory action [172]. In 
line with the involvement of an inflammatory component, post-mortem studies of 
brains of autistic patients permitted to reveal the presence of reactive glia from 
childhood to adulthood. Microglia represents the immune component of the brain 
and many insults to the nervous system lead to morphological and/or functional 
changes in these cells (micro-gliosis). If persistently maintained, the activation of 
microglia, which initially has the function to restore homeostasis in the brain, may 
be exacerbated and become detrimental [173]. In addition to microglia, also 
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astrocytes are involved in the inflammatory processes in the brain through the 
production of cytokines and through the increase in their number and dimension 
(astro-gliosis). 
Although our results clearly show that the inflammatory insult in the mother at GD9 
is able to affect the embryos inducing short-term inflammatory responses, the 
microglia analysis performed on adults does not show any evidence for the presence 
of sustained inflammatory responses in P90 brains. Thus, the increased 
susceptibility to seizures observed upon KA injection in adult mice, does not seem 
to reflect long-term chronic inflammatory processes occurring in animals prenatally 
exposed to Poly I:C. 
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EVALUATION OF THE INVOLVEMENT OF E/I BALANCE IN THE 
SUSCEPTIBILITY TO SEIZURES IN POLY I:C OFFSPRING 
 
Synaptic proteins levels are not affected by prenatal exposure to Poly I:C 
Since we did not found significant inflammatory alteration in adult brains and given 
that the susceptibility to epilepsy may result from a change in the 
excitatory/inhibitory (E/I) balance in the brain [174-176], we hypothesized that  
prenatal immune challenge could modify either the number or the function (or both) 
of synaptic contacts in the developing (E17) as well as in the adult (P90) brain. To 
address this issue, we started by analysing the protein expression levels of a battery 
of synaptic markers, including the vesicular glutamate transporter vGlut1, the GABA 
vesicular transporter vGAT, the two SNARE proteins Snap25 and syntaxin 1A, as 
well as the post-synaptic protein PSD95, by western blotting. To this aim E17 and 
P90 cortical homogenates from Poly I:C and control mice were analysed and, 
interestingly, no significant differences in synaptic protein expression was found 
between the two experimental groups at both ages (Figure 9A and 9B). Despite our 
analysis has been limited to a restricted number of proteins, these data indicate that 
the increased susceptibility to seizures of Poly I:C offspring is unlikely the result of 
an alteration of synaptic markers protein expression. 
 
 
  
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Biochemical analysis of excitatory and inhibitory pre- and post-synaptic proteins. 
Quantitative western blot analysis of the synaptic proteins vGlut1, vGAT, Snap25, Syntaxin 1A (Syntx 
1A) and PSD95 in E17 cortical homogenates (A) and in P90 homogenates (B). No differences in all the 
synaptic proteins tested were found at both ages. Student’s t-test. Ctrl n=5, Poly I:C n=6. 
 
 
Network excitability is increased in Poly I:C-prenatally exposed mice  
We then ask whether Poly I:C treatment alters synaptic transmission in cortical 
neurons. Consistent with the lack of differences in the expression of synaptic 
markers, patch clamp recordings from P15-28 (that from now for convenience we 
will call P20) acute cortical slices from Poly I:C and control mice did not reveal any 
difference in either the frequency or the amplitude of miniature excitatory 
(mEPSCs) or inhibitory (mIPSCs) post-synaptic currents (Figure 10B). 
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Figure 10. (A) Representative traces of mEPSCs and mIPSCs recorder from P20 cortical slices obtained 
from Poly I:C prenatally-treated mice and control mice. (B) Electrophysiological analysis of the 
frequency and the amplitude of excitatory and inhibitory miniature post-synaptic currents. Student’s t-
test. mEPSCs Ctrl n=7, Poly I:C n=7; mIPSCs Ctrl n=6, Poly I:C n=6. 
 
 
Conversely, and in line with the increased susceptibility to seizures, a higher 
network excitability was detected by cell-attached recordings, with a significantly 
higher spontaneous activity in Poly I:C relative to control mice (Figure 11B). 
Altogether these data indicate that Poly I:C treatment increased spontaneous 
neuronal activity in cortical neurons in the offspring, without apparently altering 
neither synaptic basal transmission nor the expression of several synaptic proteins. 
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Figure 11. (A) Representative traces of spiking activity recorded in P20 cortical slices from Poly 
I:C and control mice. (B) Quantitative analysis of the spiking activity showing an increase in the 
frequency of action-potential discharge in Poly IC: prenatally-treated mice respect to controls. 
Mann-Whitney test, *p=0,0108. Ctrl n=7, Poly I:C n=10. 
 
 
GABA signalling is altered in Poly I:C offspring due to higher intracellular 
chloride concentrations 
In order to get more insights into the molecular mechanisms responsible for higher 
neuronal activity in Poly I:C offspring, we focus our attention on GABA signalling. It 
is now well known that a change in the excitatory/inhibitory balance may result not 
only from an alteration in glutamatergic and GABAergic synaptic inputs balance, but 
also from the depolarizing/hyperpolarizing action of GABA. Indeed, at early stages 
of development, in immature neurons, GABA is depolarizing [177] and the transition 
of GABA signalling from depolarizing to hyperpolarizing, a process called “GABA 
switch”, starts soon after birth and is completed, in rodents, by the end of the first 
postnatal week [178]. It is also known that the developmentally regulated GABA 
switch is altered in several pathophysiological conditions, thus GABA still retain its 
immature excitatory role also at adult stages leading to an E/I imbalance in 
adulthood [122, 179].  
To assess whether the process of GABA switch was correctly completed in cortical 
circuits of Poly I:C offspring, we applied 200 ɥM GABA directly to cortical slices 
established from P20 control and Poly I:C offspring and we recorded spontaneous 
activity through cell-attached configuration. Striking, in contrast to control brain 
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slices in which GABA application slightly reduce spontaneous neuronal activity, in 
line with the inhibitory role of GABA signalling at this postnatal stage, Poly I:C slices 
showed an increase in neuronal activity upon GABA application (Figure 12B). 
Therefore, in the Poly I:C prenatally-exposed mice, GABA signalling still exerts an 
excitatory action, indicating the occurrence of a delayed GABA switch.  
 
 
 
 
 
Figure 12. (A) Representative traces of spiking activity recorded from P20 cortical slices obtained from 
Poly I:C and control offspring, before and after GABA application. (B) Quantitative analysis of the 
spiking activity upon application of 200 ɥM GABA. In Poly I:C brain slices neuronal firing is increased 
when GABA is applied directly on slices. Ctrl n=5, Poly I:C n=8 
 
 
The excitatory action of GABA signalling results from high intracellular chloride 
concentrations which force chloride to flow outside the cells through GABAA 
receptors thus leading to membrane depolarization [25]. This prompted us to 
directly evaluate intracellular chloride concentration ([Cl-]i) through two-photon 
imaging by means of the chloride-sensitive dye MQAE, in order to univocally 
demonstrate that the GABA switch was altered in Poly I:C cortical circuits. The 
analyses were performed in P20 cortical slices, a time at which GABA signalling is 
inhibitory in control mice (Figure 12) reflecting a completed GABA switch in such 
physiological conditions. As expected, the analysis of MQAE-fluorescence clearly 
indicated that Poly I:C mice exhibited a higher resting [Cl-]i in cortical neurons 
compared to control mice (Figure 13B), indicating a more immature phenotype in 
Poly I:C offspring.  
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Figure 13. Quantitative analysis of the intracellular chloride concentration in cortical neurons from 
P20 brain slices obtained from Poly I:C and control offspring. (A) Representative two-photon images 
showing [Cl-]I in Poly I:C and control cortical neurons. (B) The mean intensity of the fluorescent chloride-
sensitive dye MQAE in inversely proportional to the intracellular chloride concentration. MQAE mean 
intensity is significantly decreased in Poly I:C offspring indicating that [Cl-]I is significantly increased in 
Poly I:C cortical neurons respect to controls. Student’s t-test, ***p<0,001, ncells > 40 for each experimental 
group. 
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Prenatal Poly I:C triggers changes in KCC2 and NKCC1 expression leading to a 
delayed GABA switch 
The GABA switch results from a developmentally regulated expression of the Na+-
K+-2Cl− cotransporter 1 (NKCC1, Cl− importer) and the K+-Cl− cotransporter 2 (KCC2, 
Cl− exporter). The NKCC1 reduction and the parallel KCC2 increase during neuronal 
development is associated with the physiological changes in intracellular chloride 
concentrations (chloride is higher in immature neurons) leading to the 
hyperpolarizing effects of GABA in mature neurons [177, 178, 180].  
For this reason, we decided to investigate the expression of the two cotransporters 
NKCC1 and KCC2 in the two conditions. Consistently, western blotting analysis of 
cortical homogenates from P90 Poly I:C cortices displayed a significantly lower 
KCC2 amount (Figure 14A), whereas on the contrary the expression of the 
Cl− importer NKCC1 in homogenates from E17 cortices was fund to be increased in 
Poly I:C offspring respect to controls (Figure 14B). Eventually, no difference in KCC2 
expression was detected in cortices obtained from animals acutely treated with Poly 
I:C in adult stage (Figure 14C), indicating that KCC2 downregulation observed in 
Poly I:C offspring was the result of a long-lasting effect of an early inflammatory 
state.   
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Figure 14. Biochemical analyses of ion cotransporters expression in brain at different ages. (A) KCC2 
protein levels are significantly reduced in P90 cortical homogenates from Poly I:C prenatally-treated 
mice. Student’s t-test, *p=0,0466, Ctrl n=10, Poly I:C n=10. (B) NKCC1 protein levels are increased in E17 
cortical homogenates from Poly I:C embryos. Student’s t-test, *p=0,0114, Ctrl n=14, Poly I:C n=15. (C) 
No difference in KCC2 protein levels are detected when Poly I:C is administered during adulthood, in 3 
months old mice. Student’s t-test, Ctrl n=4, Poly I:C n=5. 
 
 
All together these results indicate that a single challenge to the maternal immune 
system at GD9 is able to delay the reciprocal change in the expression of NKCC1 and 
KCC2, leading to higher intracellular chloride concentrations resulting in GABA 
depolarizing activity in P20 cortical neurons. 
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NEURON DEVELOPMENTAL TRAJECTORIES ARE AFFECTED BY MIA 
THROUGH PROCESSES INTRINSICALLY MAINTAINED, 
INDEPENDENTLY FROM THE BRAIN ENVIRONMENT 
 
Our next goal was to investigate whether the altered GABA switch promoted by 
maternal immune activation w a process requiring the whole brain environment. To 
investigate this point, we took advantage of primary cultures of cortical neurons, a 
model in which whole brain integrity is lost allowing a more precise analysis on 
neuronal cells. Cortical neuronal cultures were established from E18 embryos, 9 
days after exposure to either Poly I:C (Poly I:C cultures) or vehicle (control cultures) 
and then analysed at 14 days of in vitro (DIV) development. In line with the in vivo 
results, electrophysiological recording of glutamatergic and GABAergic synaptic 
basal transmission showed no changes in Poly I:C versus control cultures at 14 DIV 
(Figure 15B). Accordingly, immunofluorescence analysis through confocal 
microscopy using antibodies against glutamate (vGlut1) or GABA (vGAT) vesicular 
transporters, to visualize glutamatergic or GABAergic synapse respectively, 
revealed no differences in the ratio between vGlut1/vGAT positive puncta (Figure 
16). Overall, these results indicate that Poly I:C treatment does not affect the density 
and functionality of glutamatergic and GABAergic synaptic contacts. 
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Figure 15. (A) Representative traces of mEPSCs and mIPSCs recorded in DIV 14 primary cortical 
neurons from Poly I:C prenatally treated embryos and controls. (B) Electrophysiological analysis of the 
frequency and the amplitude of both excitatory and inhibitory miniature post-synaptic currents shows 
no differences between the two experimental groups. Student’s t-test. mEPSCs Ctrl n=12, Poly I:C=12; 
mIPSCs Ctrl n=11, Poly I:C n=14. 
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Figure 16. Immunocytochemical experiments on 14 DIV primary cortical neurons from Poly I:C and 
control embryos. (A) Representative confocal images showing presynaptic excitatory marker vGlut1 in 
blue and the presynaptic inhibitory marker vGAT in red. (B and C) Quantitative analysis of the number 
of positive vGlut1 and vGAT puncta over the total number of vGlut1 and vGAT positive puncta showing 
no differences between the two experimental groups. Student’s t-test, n=3 coverslips for each 
experimental group. 
 
 
However, and in line with our in vivo data, Poly I:C cultures displayed a significantly 
higher frequency of both long bursts of action potentials, recorded in whole cell 
configuration, (Figure 17C), and multi-unit (MU) activity, recorded in cell-attached 
configuration (Figure 17D), thus suggesting again a possible unbalanced 
excitatory/inhibitory input onto these neurons. 
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Figure 17. (A) Representative trace of bursts of action potentials. (B) Representative traces of Multi 
Units. (C) Quantitative analysis of the burst activity recorded in 14 DIV primary cortical neurons 
indicating a higher frequency of long bursts of action potentials in the Poly I:C cultures. Student’s t-test, 
**p<0,01. Ctrl ncells=23, Poly I:C ncells=28 (D) Quantitative analysis of the spiking activity by multi-units 
recording in 14 DIV primary cortical neurons. Student’s t-test, **p<0,01. Ctrl ncells=27, Poly I:C ncells=28. 
 
 
To investigate whether a delay in the GABA switch could be at the origin of this 
altered electrophysiological behaviour, we firstly evaluated GABA-mediated 
calcium transients in both neuronal cultures. Neurons were loaded with the calcium 
sensitive dye Fura-2AM and subsequently exposed to 100 ɥM GABA. Since it is 
described that at DIV 6 about 50-60% of neurons still respond to GABA with 
depolarizing calcium transients [181], we decided to use 6 DIV neurons as optimal 
time point for these experiments. Consistent with the observed GABA-mediated 
depolarizing activity in P20 cortical slices, we found that Poly I:C cultures exhibited 
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a higher number of GABA-responding neurons than control cultures (Figure 18), 
thus indicating a delayed GABA switch in neurons established from prenatally Poly 
I:C-treated embryos respect to controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Quantitative analysis of the number of 6 DIV primary cortical neurons responding to GABA 
application by depolarization. Student’s t-test *p<0,027. Ctrl ncells= 538, Poly I:C ncells=661 
 
 
In parallel, cultures were loaded with the chloride-sensitive dye MQAE and 
intracellular chloride concentration was evaluated in the two conditions. Consistent 
with this evidence, 6 DIV chloride imaging showed a higher [Cl-]i in Poly I:C cultures 
compared to control cultures (Figure 19B), thus further supporting the evidence of 
an altered GABA switch in primary cultures established from Poly I:C prenatally-
exposed embryos. Furthermore, significantly lower levels of KCC2 and higher levels 
of NKCC1 were detected by western blotting analysis in 6 DIV Poly I:C cultures 
relative to controls (Figure 19 C and D). 
Therefore, considering all these in vitro results, we can conclude that the molecular 
consequences of an early immune challenge occurring in neurons at GD9 in the vital 
embryo remain sculpted in the developmental program of neurons even when they 
are isolated from the brain environment and maintained in primary cultures. 
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Figure 19. Intracellular chloride measurements in 6 DIV primary cortical neurons established from 
Poly I:C and control embryos. (A) Representative images showing the fluorescence variation of the 
chloride sensitive dye MQAE n the 2 type of cultures. (B) Quantitative analysis of the MQAE mean 
intensity. Like in the in vivo experiments a lower MQAE mean intensity in the Poly I:C cultures indicates 
an increased [Cl-]i. Student’s t-test, ****p<0,0001. (C and D) KCC2 and NKCC1 protein levels measured 
by western blotting experiments. Student’s t-test, *p<0,05, Ctrl n=5, Poly I:C n=5 (E) Representative 
western blot lanes. 
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PREVENTIVE EFFECTS OF MAGNESIUM SULFATE ADMINISTRATION 
DURING PREGNANCY 
 
Magnesium is reported to have several effects at early stages of development, 
including neuroprotective [182, 183] and anti-inflammatory effects [38-40]. A 
randomized clinical trial by Rouse and colleagues [184] showed a significantly lower 
rate of cerebral palsy, a group of permanent movement disorders caused by 
abnormal development or damages in the brain occurring during pregnancy, in 
preterm born infants who received magnesium sulfate (MgSO4) before delivery. 
This protective association was robust and persisted after controlling for multiple 
confounders. Moreover, the association was biologically plausible because 
magnesium it is known to reduce vascular instability, hypoxic damage and protect 
against cytokine or excitatory amino acid damage, all threats to the vulnerable 
preterm brain [185]. A more recent meta-analysis by Doyle and colleagues 
confirmed the neuroprotective effects of maternal MgSO4 administration [186]. 
Besides the clinical evidence of the neuroprotective activity of magnesium, pre-
clinical studies on rodents demonstrated that magnesium sulfate is able to reduce 
inflammation at the maternal-fetal interface following LPS administration in the 
mother during pregnancy [187]. Moreover, short- and long-term changes in the 
inflammatory status in pregnancies complicated by pathologies such as pre-
eclampsia are reported [188] and magnesium seems to have beneficial effects by 
reducing IL-6 [189] and IL-1β  levels [190] in the mother circulation as well as in the 
placental compartment. Not less important is the fact that one of the largest clinical 
study on eclamptic events prevention during pregnancy, the Magnesium Sulfate for 
Prevention of Eclampsia or Magpie Trial, demonstrated that treatment with 
magnesium sulfate is able to lower the number of patients who developed eclampsia 
by about half, without any serious harmful effects on either the mother or fetus 
[191]. It seems clear that, despite the exact mechanism through which magnesium 
exerts its beneficial effects is not yet known, its neuroprotective, anti-inflammatory 
and vasodilatory properties are supported by several studies. 
All these knowledges about magnesium prompt us to investigate whether the effects 
of prenatal immune activation on the offspring could be prevented by using 
magnesium sulfate in the mother. First, we investigated whether the treatment with 
MgSO4, prior to Poly I:C injection, could prevent the very rapid increase of IL-6 in 
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the maternal plasma. Surprisingly we found that IL-6 levels in females pre-treated 
with magnesium were comparable to control levels (Figure 20A). 
 
 
 
 
 
Figure 7. (A) Quantitative analysis of IL-6 plasmatic levels in adult females 3 hours after Poly I:C 
injection alone or MgSO4 treatment prior to Poly I:C. MgSO4 is able to prevent the increase in IL-6 
plasmatic levels observed with the Poly I:C alone. Ordinary one-way ANOVA followed by Tukey's multiple 
comparisons test, ***p<0,001. (B). Quantitative analysis of IL-6 mRNA levels in whole embryos 6 hours 
after Poly or MgSO4+Poly I:C in the mother. MgSO4 is able to prevent the increase in IL-6 mRNA levels 
observed in the Poly I:C embryos. Ordinary one-way ANOVA followed by Tukey's multiple comparisons 
test, *p<0,05, **p<0,01. Ctrl n=8, Poly I:C n=10, MgSO4 alone n=5, MgSO4+Poly I:C n=14. 
 
 
In addition, we investigated the IL-6 mRNA levels in embryos exposed to MgSO4 pre-
treatment in the mother and, very interestingly, we found that MgSO4 is able to 
prevent IL-6 increase in whole embryos 6 hours after Poly I:C injection. Magnesium 
itself seems to have no effects on IL-6 expression (Figure 20B). 
We then asked whether magnesium administration before Poly I:C injection in the 
mother could somehow prevent the increased susceptibility to seizures observed in 
the Poly I:C offspring. Strikingly, P90 offspring from Magnesium-Poly I:C treated 
dams resulted less susceptible to KA induced seizures respect to Poly I:C mice, with 
a behavioural trend fully comparable with the control offspring (Figure 21). 
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Figure 8. Time course of the behavioural response to 35 mg/kg kainate injection in control, Poly I:C and 
MgSO4+Poly I:C injected offspring. Notably, MgSO4 is able to prevent increase seizure susceptibility when 
administered in the mother before Poly I:C. 
 
 
We then wanted to investigate whether the restoration of a physiological 
susceptibility of epileptic by MgSO4 was associated with a normalization of 
intracellular chloride concentrations in the Poly I:C. offspring cortical neurons. We 
then performed two-photon imaging also in P20 cortical slices from offspring 
prenatally treated with magnesium prior to Poly I:C. In line with what expected, we 
found that MgSO4 treatment could prevent the increased intracellular chloride 
concentration observed in Poly I:C offspring (Figure 22A), by restoring these levels 
to values comparable to control mice. Consistently with this data, we found no 
changes in KCC2 protein levels in P90 Poly I:C offspring pre-treated with MgSO4 
respect to control mice (Figure 22B), further suggesting that magnesium, probably 
via cytokine-activated pathways or via other pathways that still need to be 
investigated, is able to prevent the altered intracellular chloride concentrations and 
KCC2 protein expression observed in Poly I:C offspring. 
 
 
65 
 
 
 
Figure 9. (A) Quantitative analysis of intracellular [Cl-] by two-photon imaging on P20 brain slices. 
MgSO4 prior to Poly I:C is able to prevent the increase in [Cl-]i observe in the offspring prenatally treated 
with Poly I:C alone. Ordinary one-way ANOVA followed by Tukey's multiple comparisons test *p<0,05, 
**p<0,01, ***p<0,001, ncells > 40 for each experimental group. (B) KCC2 protein levels are reduced by 
Poly I:C prenatal treatment but not by combined administration of both MgSO4 and Poly I:C. One-way 
ANOVA followed by Tukey's multiple comparisons test, *p<0,05. Ctrl n=10, Poly I:C n=10, MgSO4+Poly 
I:C n=4. 
 
 
Besides providing the direct demonstration that the increased susceptibility to 
seizures following prenatal immune activation stems from an altered GABA switch 
due to aberrant intracellular chloride homeostasis, these data open the possibility 
of a potential strategy to prevent harmful effects of prenatal immune activation on 
the fetal brain. 
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TIME OF PRENATAL IMMUNE CHALLENGE DIFFERENTIALLY 
AFFECTS INTRACELLULAR CHLORIDE CONCENTRATION  
 
The development of the human CNS begins early during the embryonic period and 
proceeds through a series of very complex processes long after delivery. Although 
the neurodevelopmental processes are genetically determined, their complexity 
implicates the vulnerability of the CNS to several environmental factors [192]. As 
extensively discussed in the introduction, timing of prenatal immune activation may 
differentially impact the developing fetus, since the maternal immune system 
exhibits considerable fluctuations as pregnancy proceeds. The associated changes 
in cytokines production may therefore critically modulate the specificity of the 
inflammatory events in the developing fetus, possibly leading to aberrant brain 
development and related behavioural and cognitive alterations later in life [30]. 
Therefore, depending on the gestational period the developing nervous system of 
the fetus may not be uniformly vulnerable to maternal infections.  
In order to assess whether GD9 represents a specific window of vulnerability for the 
onset of the behavioural but also biochemical and functional alterations observed 
following Poly I:C challenge, we administered the same dosage (2 mg/kg) at later 
developmental stages during pregnancy.  With the same modality GD15 pregnant 
dams were injected with either Poly I:C or vehicle ip. and intracellular chloride 
concentrations were examined in cortical neurons from P20 acute brain slices from 
Poly I:C and control offspring. We interestingly found that unlike GD9 
administration, Poly I:C administration at GD15 results in the opposite phenotype. 
In fact, two-photon microscopy showed a decrease in [Cl−]i, in Poly I:C offspring as 
compared to control, as highlighted by the corresponding increase in the MQAE 
mean lifetime (Figure 23).  
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Figure 23. Quantitative analysis of the intracellular chloride concentration in cortical neurons from 
P20 brain slices obtained from Poly I:C and control offspring at the two gestational ages, GD9 and GD15. 
The mean lifetime of the fluorescent chloride-sensitive dye MQAE in inversely proportional to the 
intracellular chloride concentration. MQAE mean lifetime is significantly decreased in GD9-Poly I:C 
offspring, indicating that [Cl-]I is significantly increased in Poly I:C cortical neurons respect to controls. 
On the other hand, the [Cl-]I is significantly decreased in offspring from GD15-Poly I:C dams. Ordinary 
one-way ANOVA followed by Tukey's multiple comparisons test, ***p<0,001; ncells > 40 for each 
experimental group. 
 
Although further experiments need to be performed in order to clarify the causes 
underlying the opposite effect induced by Poly I:C at the two gestational times, it 
seems clear that two distinct temporal windows corresponding to mid- (GD9) and 
late-(GD15) gestation, are crucial in determining specific outcomes of prenatal 
immune activation.  
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REST AND MeCP2 BINDING TO KCC2 PROMOTER IS INCREASED IN 
POLY I:C OFFSPRING 
 
Our evidence clearly indicates that a single immune activation at early stages of fetal 
brain development is sufficient to induce long-lasting modifications in the offspring 
brain, thus suggesting possible genetic or epigenetic mechanisms underlying. In an 
attempt to explore the molecular underpinnings of this phenomenon, we pointed 
our attention on possible molecular players which are known to have a fundamental 
role in modulating chromatin state during brain development [193].  Indeed, 
chromatin modifiers, such as DNA methyltransferases, histone methyltransferases 
and histone acetyltransferases, are recruited to specific genomic loci by DNA 
binding proteins,  altering the access of specific transcription factors to chromatin 
thus modulating gene expression [194]. A good candidate for orchestrating 
epigenetic events in the nervous system is the DNA binding protein REST (Repressor 
Element 1 Silencing Transcription Factor), also known as the Neuron-restrictive 
Silencer Factor (NRSF). REST was firstly discovered in 1995 as a repressor of 
neuronal genes containing a 23 bp conserved motif known as RE-1 (repressor 
element 1 or NRSE) sequences. It plays a pivotal role in maintaining the 
transcriptional silencing of a large number of neuronal genes in non-neuronal 
differentiated cells, as well as in un-differentiated neuronal cells during early stages 
of neurogenesis, by recruiting  a co-repressor complex containing CoREST [195] 
histone deacetylases (HDACs) [196-198] and methyl CpG-binding protein MeCP2 
[199]. Downregulation of REST during transition from progenitors to post-mitotic 
neurons is necessary to allow neuronal gene expression [200], so that neuronal 
development can occur properly.  Because RE-1 sequences was initially found only 
in neuronal genes, REST was assumed to be a master regulator of neurogenesis 
[201-203], but subsequently it has been implicated in more complex gene regulation 
such as the maintenance of embryonic stem cell pluripotency and self-renewal and 
regulation of mitotic fidelity in non-neural cells [193, 204]. In addition, REST 
dysfunction has been implicated in several diseases ranging from Down’s syndrome 
to cardiomyopathies and cancer, as well as in epilepsy and ischemia [205-207] 
emphasizing its importance also as a master regulator of normal gene expression 
programs [208]. Interestingly, REST repressor complex is known to be involved in 
the regulation of KCC2 expression in neurons by binding to both RE-1 elements 
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located in the KCC2 gene, one in the promoter of the gene, the second one 
downstream the TSS (transcriptional start site), in the intronic region of the gene 
[209]. 
Since we found reduced levels of KCC2 and associated alterations in intracellular 
chloride concentration following prenatal Poly I:C exposure, both in vitro and in vivo, 
we investigated the possible involvement of REST in our model. Taking advantage 
of ChIP (chromatin immunoprecipitation) experiments we investigated the possible 
interaction between REST and the KCC2 promoter in P20 cortices from Poly I:C and 
control offspring. Remarkably, we found that prenatal exposure to Poly I:C results 
in an increased binding of REST to the RE-1 element in the promoter of KCC2 gene 
(fragment 509), as well as to the RE-1 element located downstream the TSS 
(fragment 524) (Figure 24B). These results are in line with the downregulation of 
KCC2 mRNA levels observed by quantitative real-time PCR in the same Poly I:C 
animals compared to controls (Figure 24C).   
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Figure 24. (A) Schematic representation of mouse KCC2 promoter with the transcriptional start site 
(TSS) and the double RE-1 repressor sites (modified from Yeo et al. 2009 [209]). (B) ChIP analysis on 
P20 cortical tissue from Poly I:C and control offspring. An upward trend was observed in the binding of 
REST to both the RE-1 sites in the KCC2 gene. Ctrl n=3, Poly I:C n=5. (C) KCC2 mRNA expression levels 
analysed by quantitative real-time PCR in P20 mice prenatally treated with Poly I:C or vehicle. KCC2 
expression is significantly decreased in Poly I:C animals respect to controls. Ctrl n=11, Poly I:C n=13, 
Student’s t-test *p=0,0401. 
 
 
  
A
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As previously discussed, another important target for epigenetic modifications in 
models of neurodevelopment is represented by MeCP2 [74]. MeCP2 deregulation 
has a well-established role in Rett’s syndrome but it has also been implicated in 
other neurodevelopmental disorders such as autism and schizophrenia [77]. 
Moreover, a first experimental demonstration that inflammation during prenatal life 
is associated with epigenetic changes, including MeCP2 promoter hypomethylation, 
has been reported in 2014 by Basil and colleagues [74]. Given the possible 
implications of MeCP2 in the regulation of neuronal genes in neurodevelopmental 
pathologies, we decided to investigate MeCP2 binding to KCC2 promoter in the same 
samples used for REST ChIP analyses. Unexpectedly, we found an increase also in 
MeCP2 binding in both regions of the gene (509 and 524), containing the two RE-1 
sites (Figure 25). 
 
 
 
Figure 25. ChIP analysis of P20 cortical tissue from Poly I:C and control offspring. An upward trend was 
observed in the binding of MeCP2 to both the RE-1 sites in the KCC2 gene. Ctrl n=3, Poly I:C n=5. 
 
 
Although further experiments are required for shedding light into such mechanisms, 
we can speculate that prenatal Poly I:C could induce epigenetic modifications on 
KCC2 gene, leading to an increased binding of the transcriptional regulators, REST 
and MeCP2, to the gene. This increased binding could result in the KCC2 
downregulation we observed, leading to the pathological deregulation of neuronal 
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chloride concentrations, thus resulting in increased network excitability a seizure 
susceptibility.  
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DISCUSSION 
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Animal models based on maternal exposure to immune stimuli allowed to explore 
the consequences of prenatal immune activation on brain development, thus 
shedding light on the molecular and cellular mechanisms underlying such 
phenomenon. The most common immunogens used in pregnant rodents are 
lipopolysaccharide (LPS), a component of the Gram-negative bacteria cell wall that 
binds to toll-like receptor (TLR) 4 mimicking bacterial infections, or 
polyinosinic:polycytidylic acid (Poly I:C), a synthetic double-strand RNA which, as 
viral nucleic acids, binds TLR3. These immunogens initiates a signalling cascade 
leading to the production of inflammatory mediators such as cytokines (IL-1β, IL-6, 
TNFα), chemokines, and complement proteins [210]. Interestingly, the injection of 
these inflammation-triggering molecules at different timepoints during gestation 
leads to different neuropathological features [30] and gene expression profiles [21]. 
Consistently, the time of prenatal immune challenge critically influences the pattern 
of behavioural abnormalities displayed by the offspring in the adult age [30]. As in 
human infections, the effects of the immune challenge on fetal brain development 
are not due to the immunogen itself but rather to the induction of pro-inflammatory 
cytokines in the maternal circulation or placenta [26, 56], including IL-6 [61]. 
Notably, existing data indicate that the inflammatory cytokine IL-6 might be a 
pivotal immunological mediator of the link between maternal immune activation 
and altered brain development including schizophrenia, autism and epilepsy [211-
213]. Indeed, the administration of exogenous IL-6 alone to pregnant animals is 
sufficient to induce long-lasting structural and functional abnormalities in the adult 
offspring, some of which are highly comparable to those induced by prenatal 
exposure to other immune activating agents such as Poly I:C [61, 214].  
 
A recent population-based cohort study demonstrated an association between 
maternal infections during pregnancy and childhood epilepsy [115]. This is 
particularly relevant given that epilepsy is highly comorbid with different 
neurodevelopmental diseases [215]. Consistent with the epidemiological data, a 
recent study demonstrates that offspring of mice which have been chronically 
exposed to Poly I:C (GD12-GD16) during pregnancy show increased hippocampal 
excitability, faster progression of kindled seizures and prolonged persistence of the 
kindling state, along with impaired social interactions [117, 164].  
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Our model provides further support to these data adding the key information that 
even a single intrauterine exposure to 2 mg/kg Poly I:C at GD9 is able to significantly 
increase offspring susceptibility to seizures induced by kainic acid injection (Figure 
2).  
 
The evidence collected in this work about the absence of a chronic inflammatory 
condition in the brain of adult offspring is quite relevant, since different papers 
reported the occurrence of major brain alterations following maternal immune 
activation. Indeed, complex and long lasting changes in inflammatory cytokines 
levels (including IL-6 and IL-1β) have been reported  in the neocortex and 
hippocampus [216, 217] in offspring from mother subjected to MIA, with relevant 
consequences on brain structure, neurogenesis and microglia activation [218, 219]. 
Furthermore, it is also known that pro-inflammatory molecules per se may increase 
epileptic susceptibility. Indeed, high IL-1β levels in the brain act as pro-convulsive 
in the kainic acid model of temporal lobe epilepsy [101] and increased levels of 
serum IL-6 occur in epileptic patients, with IL-6 levels directly correlating with 
seizures frequency [220]. In contrast to a possible inflammation-based hypothesis 
underlying the enhanced susceptibility to seizures observed in MIA offspring, we 
failed in detecting any significant variations of either IL-6 or IL-1β mRNA levels in 
MIA offspring mice. Although the apparent discrepancy between our data and that 
of other groups might be the result of different dosage and timing of Poly I:C 
injection, our data clearly indicates that the enhanced susceptibility to seizures does 
not result from an enduring elevation in cytokine expression. 
  
The results reported in this study, point to alterations in neuronal chloride 
transporters expression, KCC2 and NKCC1 (Figure 14A), as the main causes of the 
neuronal network hyperexcitability observed in cortical neurons of Poly I:C 
offspring (Figure 11). In particular, several works indicate that KCC2 reduction 
results in an increased neuronal network excitability. Indeed, reduction of surface 
expression of KCC2 has been described to render neuronal networks hyperexcitable 
and susceptible to seizures triggered by excitatory stimuli [221], while mutations in 
the Drosophila melanogaster KCC gene kazachoc (kcc) confer increased seizure 
susceptibility [222]. Moreover, KCC2 heterozygous mice, expressing ~50% of the 
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wild-type KCC2 protein, show increased susceptibility to pentylenetetrazole-
induced seizures [148] and  a KCC2 co-segregating variant (KCC2-R952H), which 
reduces neuronal Cl− extrusion, has been described in an Australian family with 
febrile seizures [155]. 
 
Interestingly, the alteration of intracellular chloride concentrations upon Poly I:C 
administration, which is responsible for the excitatory role of GABA signalling in our 
model, is tightly dependent on the developmental stages of Poly I:C injection. In fact, 
when administered at GD9, Poly I:C induces an increase in intracellular chloride 
concentrations of cortical neurons (Figure 14), while in contrast and unexpectedly, 
at GD15 the effect is the opposite (Figure 23), probably leading to different 
outcomes in the offspring. Certainly, GD9 and GD15 represent two very distinct 
stages of brain development. In mice, GD9 corresponds to a very precocious stage of 
neurodevelopment, when cortical neurogenesis is about to get started; cortical layer 
I is the first to be shaped during neurogenesis from E10.5 to E12.5 [223] while layers 
IV, V and VI are formed during E11.5 - E14. Layers II and III are the last to be formed 
during corticogenesis around E13.5 to E16 and include pyramidal neurons, stellate 
neurons and radial glial cells [224] as layer IV, V and VI. On the other hand, at GD15 
the cortical layering is almost completed and the mouse blood brain barrier is 
almost completely functional (E15.5) [225]. When administered at GD9 or at GD15, 
Poly I:C impact on two very different stages of embryonic development and it would 
not be so surprising if the maternal response to Poly I:C was different at the two 
times. In this regard, it has been widely demonstrated that the maternal innate 
immune system is very dynamic during gestation and that TLRs are differentially 
expressed in non-pregnant, compared with pregnant tissues [226]. Moreover, TLR3 
expression is increased from the first to the third trimesters in humans and Poly I:C 
is able to reduce its expression during the third trimester with no effects in the first 
trimester. Thus, it would be very interesting to investigate the pattern of 
inflammatory cytokines expressed both by the mothers and the embryos when Poly 
I:C is administered at GD15 rather than at GD9. Moreover, the precise timing of 
prenatal immune challenge critically determines the specificity of behavioural 
pathology, a concept which is clearly demonstrated in preclinical models. Poly I:C 
challenge on GD9 suppresses spatial exploration, whereas the same treatment 
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conducted on GD17 leads to perseverative behaviour [30]. Hence, since the 
specificity of the offspring vulnerability may depend on the gestational time 
windows at which the maternal immune system is challenged, further experiments 
will help us to clarify the causes underlying the opposite phenotypes observed at 
the two gestational ages in our model. 
 
Despite our results exclude a contribution of persistent elevated cytokine levels in 
the brain of adult offspring, we believe that the transient increase in IL-6 and IL-1β 
occurring in the fetuses (Figure 5), few hours after Poly I:C injection in the mother, 
is at the root of the developmental trajectory leading to KCC2 dysregulation. Indeed, 
we observed that maternal dietary supplementation with MgSO4 was sufficient to 
prevent fetal cytokines transient increase (Figure 20) as well as the increase in [Cl−]i 
in cortical neurons and KCC2 deregulation (Figure 22), thus also avoiding the 
increase in seizures susceptibility (Figure 21) observed upon prenatal Poly I:C 
administration. MgSO4 is reported to have several effects at early developmental 
stages, including neuroprotective [182, 183] and anti-inflammatory properties [38-
40] and in our model resulted to be effective in preventing the early inflammatory 
state associated to maternal immune activation.  
 
It is known that KCC2 is the only one of the nine KCC isoforms to be exclusively 
expressed in central neurons [227] and its lack in non-neuronal cells relies on REST 
repression through the binding to the RE-1 site located in the KCC2 promoter [228]. 
In addition, REST repressor complex regulates the expression of KCC2 in neurons 
by binding to two RE-1 sites in the KCC2 gene [209], allowing its progressive 
increase during neurodevelopment, necessary for correct brain maturation and 
functioning. It has been reported that the alteration of KCC2 expression through  
REST activity can modify the chloride switch in cortical neurons [209]. Accordingly, 
by ChIP experiments we found an increase in REST binding to KCC2 gene following 
prenatal Poly I:C administration respect to controls (Figure 24), consistent with a 
downregulation of KCC2 mRNA expression levels. Moreover, another important 
master regulator of neuronal genes transcription, MeCP2, was found to be tightly 
bound to KCC2 RE-1 sites in Poly I:C offspring respect to controls (Figure 25). It is 
known that MeCP2 binds to the N-terminus domain of REST in the REST complex, 
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(Figure 26) and it has been demonstrated that both upstream and intronic RE-1 sites 
are bounded by REST, as well as by the corepressors MeCP2 and CoREST with a 
relative binding of MeCP2 and CoREST to the intronic RE-1 higher than that 
measured for the upstream RE-1 by ChIP analyses; suggesting a tighter association 
of REST and MeCP2 with the intronic RE-1 [209].  
 
 
 
 
Figure 26. Schematic picture showing REST complex–RE-1 binding interaction at the KCC2 promoter, 
from Yeo et al. 2009.  
 
 
 
Since MeCP2 is part of the REST repressor complex responsible for the regulation of 
KCC2 expression, it is possible that REST and MeCP2 could cooperate together in the 
regulation of KCC2 expression rather than compete for the binding to the RE-1 sites 
as recently suggested in a paper by Tang et al. [229]. Thus, we hypothesize that 
prenatal Poly I:C could lead to an increase in the repression of KCC2, probably by 
epigenetic modifications on chromatin in the KCC2 gene thus altering the binding of 
the REST complex (including MeCP2). Further experiments, like for example 
analyses of changes in chromatin structure, like histone methylation levels, in the 
KCC2 gene, must be performed in order to further investigate the mechanism 
underlying KCC2 deregulation. 
 
Despite several studies on KCC2 expression, no data are reported about a possible 
role of REST in regulating NKCC1 expression. Since both NKCC1 and KCC2 are 
involved in chloride homeostasis and in the GABA switch during neurodevelopment, 
and since in our model we found not only a decrease in KCC2 levels but also an 
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increase in NKCC1 protein levels in E17 cortices from Poly I:C offspring and in 6 DIV 
Poly I:C-established cultures, it will be necessary to investigate why and how NKCC1 
is dysregulated in our Poly I:C model. 
 
Since at the root of the phenotype observed upon Poly I:C immune challenge there 
could be epigenetic modifications leading to KCC2 dysregulation responsible for 
increased network excitability, we can speculate that maternal immune activation 
could change neuron developmental trajectories through epigenetic processes 
which are intrinsically “sculpted” in the neuron, independently from the brain 
environment, as demonstrated by in vitro experiments from Poly I:C cultures 
recapitulating ex vivo and in vivo observations (Figure 15-19).  
 
A number of  studies have examined the possible role of furosemide and 
bumetanide, two widely-used diuretic drugs, in the treatment of epileptic disorders, 
since these two drugs can inhibit cation-chloride cotransporters [230]. While these 
and other observations indicate an anticonvulsant action of these drugs, novel 
compounds, also including KCC2 activators, are needed for further research on CCCs 
as pharmacotherapeutic targets. Indeed, recent reports indicate that enhancing 
KCC2 activity may be the best therapeutic strategy to restore inhibition and normal 
function in pathological conditions involving impaired Cl− transport [231, 232]. 
Gagnon and colleagues identified a KCC2-selective analogue (CLP257) able to 
reduce [Cl−]i, restoring the impaired Cl− transport in neurons with diminished KCC2 
activity. The compound rescued KCC2 plasma membrane expression, renormalized 
stimulus-evoked responses in spinal nociceptive pathways sensitized after nerve 
injury and alleviated hypersensitivity in a rat model of neuropathic pain [233]. 
These results validate KCC2 as a novel therapeutic target for CNS diseases, opening 
the possibility to use this kind of compounds for the treatment of a wide range of 
neurological and psychiatric disorders, since it is known that KCC2 dysfunction and 
Cl− homeostasis are central to many CNS disorders including epilepsy, stress, 
anxiety and schizophrenia. Thus, it could be interesting to evaluate if such 
compounds could be effective in the treatment of the pathological conditions we 
observed following prenatal Poly I:C in our model.  
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In conclusion, using the Poly I:C model of maternal immune activation, we provide 
here the evidence that a single prenatal stimulus, during a selected time window of 
pregnancy (GD9), affects the glutamate-GABA equilibrium in the offspring through 
a long-lasting alteration of the chloride transporter KCC2 expression at cortical 
level, resulting in an alteration of the hyperpolarizing action of GABA which endures 
at mature stages, as highlighted by increased seizure susceptibility. We also provide 
the proof-of-concept that such protein expression abnormality and its deleterious 
physiological consequences can be prevented by dietary maternal supplementation 
with MgSO4, already known to reduce inflammation at the maternal-fetal interface. 
Notably, the increased binding of the two master regulators of neuronal genes 
expression, REST and MeCP2, on KCC2 promoter, suggests a possible epigenetic 
mechanism involved in the regulation of KCC2 expression following inflammation 
in the mother. Thus, maternal immune activation, through pro-inflammatory 
cytokines, may lead to epigenetic modification responsible for KCC2 dysregulation 
and the consequent pathological outcomes, as suggested also by in vitro 
experiments. 
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EXPERIMENTAL PROCEDURES 
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ANIMALS 
Wild type C57BL/6 mice (Charles River) were used. Animals were housed at 
constant temperature (22-18°C) and relative humidity (50%) under a regular light–
dark schedule (lights on 7 a.m. to 7 p.m.) with food and water ad libitum. All the 
experimental procedures were carried out following the guidelines established by 
the Italian Council on Animal Care and were approved by the Italian Government 
Decree No. 27/2010 and the Italian Legislation (L.D. No 26/2014). All efforts were 
made to minimize animal suffering and to use only the number of animals necessary 
to produce reliable scientific data.  
 
 
MATERNAL IMMUNE ACTIVATION 
Three to six months old females were mated for 24 hours with a single male. Starting 
from gestational day 0 (GD0) females were weighed every 2 days till GD9. At GD9 
females who gained at least 1,5 grams, gradually in time, were injected with 2 mg/kg 
body weight Poly I:C (polyinosinic:polycytidylic acid, Sigma-Aldrich) or vehicle 
intraperitoneally (ip.). Pregnant females were then used to obtain embryos at 
different stages of embryonic development or the offspring was allowed to be born 
and grow till postnatal day 20 (P20) or P90. 
 
 
ELISA FOR IL6  
Three months old females were treated with vehicle or 2 mg/kg Poly I:C ip. Three 
hours after the injection the animals were sacrificed and the blood was collected and 
placed in tubes containing 4.1 mM EDTA used as anticoagulant. After centrifugation 
at 2000 g for 15 minutes the plasma was collected and used to evaluate IL-6 levels 
using a IL-6 specific ELISA kit (Thermo Fisher Scientific), with 50-2000 pg/ml 
sensitivity, according to the instructions from the manufacturer. The absorbance 
was then measured at 450 and 550 nm using Victor2 spectrophotometer (Wallac). 
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BEHAVIOURAL OBSERVATION OF KAINIC ACID-INDUCED SEIZURES 
Kainic Acid (KA, Sigma-Aldrich) was dissolved in saline solution and administered 
ip. 35 mg/kg body weight. P90 control and Poly I:C-offspring mice were used. In all 
experiments, the experimenter was blind to the treatment of the animals. Seizure 
severity was determined according to the Racine’s scale [234]: stage 0: normal 
behaviour; stage 1: immobility; stage 2: forelimb and/or tail extension, rigid 
posture; stage 3: repetitive movements, head bobbing; stage 4: forelimb clonus with 
rearing and falling (limbic motor seizure); stage 5: continuous rearing and falling; 
stage 6: severe whole body convulsions (tonic-clonic seizures); stage 7: death. For 
each animal, the rating scale value was scored every ten minutes for a maximum of 
3 hours after KA administration. The data were used to calculate the time-course of 
seizure severity for each experimental group. 
 
 
BRAIN SLICE PREPARATION FOR IMMUNOFLUORESCENCE 
STAINING 
P90 brains from Poly I:C prenatally-treated mice and controls were used. Animals 
were first euthanized and then perfused transcardially with 4% paraformaldehyde 
in 0,1 M phosphate buffer, pH 7.2 as described by Frassoni et al. [235]. Forebrains 
were dissected out and coronally cut with a VT1000S vibratome (Leica 
Microsystems) in serial sections. The following primary antibodies were used: anti-
rabbit IBA1 (1:200; Wako), anti-rat CD11b (1:1000, Biolegend). Free-floating 
sections were preincubated for 45 min in 0.01 M phosphate buffered saline pH 7.4, 
containing 10% normal goat serum and 0.1% Triton X-100 and then incubated with 
primary antibodies. Subsequently the sections were incubated with the 
corresponding secondary fluorescent antibodies conjugated with Alexa-488, Alexa-
555 or Alexa-633 fluorophores (Invitrogen). Slices were then put on coverslips by 
the use of the aqueous mounting medium Fluorsave (Millipore) and maintained at -
20°C.  
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SKELETON ANALYSIS 
The skeleton analysis is a quantitative method that enables to analyse 
morphological features of microglial cells through IF images obtained from brain 
slices acquired by confocal microscopy. We obtained a projection of the maximum 
intensity of the IBA1-positive signal to be able to fully visualize all the microglial cell 
processes. The resulting image was then converted to a binary image and 
skeletonized before using the plugin from ImageJ software: AnalyzeSkeleton plugin. 
The data from this analysis were then normalized to the number of cells present in 
the image as described [236]. 
 
 
BRAIN SLICE PREPARATION FOR ELECTROPHYSIOLOGY 
Poly I:C and control offspring, aged 17-28 days were deeply anesthetized with ether 
and decapitated. Brains were removed and placed in ice-cold solution containing the 
following (in millimolar): 87 NaCl, 21 NaHCO3, 1.25 NaH2PO4, 7 MgCl2, 0.5 CaCl2, 2.5 
KCl, 25 D-glucose and 7 sucrose, equilibrated with 95% O2 and 5% CO2 (pH 7.4). 
Coronal slices (300 µm thick) were cut with a VT1000S vibratome (Leica 
Microsystems) from medial prefrontal cortex. Slices were incubated at room 
temperature for at least 1 h, in the same solution as above, before being transferred 
to the recording chamber. During experiments, slices were superfused at 1.0 ml/min 
with artificial cerebrospinal fluid containing the following (in millimolar): 135 NaCl, 
21 NaHCO3, 0.6 CaCl2, 3 KCl, 1.25 NaH2PO4, 1.8 MgSO4, and 10 D-glucose, aerated 
with 95% O2 and 5% CO2 (pH 7.4). Cells were examined with a BX51WI upright 
microscope (Olympus) equipped with a water immersion differential interference 
contrast (DIC) objective and an infrared (IR) camera (XM10r Olympus). 
 
 
IN VIVO WHOLE-CELL RECORDINGS 
Neurons were voltage (or current) clamped with a Multiclamp 700B patch-clamp 
amplifier (Molecular Devices, Union City, CA) at room temperature. Low-resistance 
micropipettes (2-3 MΩ) were pulled from borosilicate. The cell capacitance and 
series resistance were always compensated. Experiments in which series resistance 
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did not remain below 10 MΩ (typically 5-8 MΩ) were discarded. Input resistance 
was generally close to 100-200 MΩ. Synaptic currents were low-pass filtered at 2 
kHz, sampled at 10 kHz and analysed with pClamp/Digidata 1440A (Molecular 
Devices). Pipettes contained (in millimolar) 135 Kgluconate, 5 KCl, 2 MgCl2, 10 
HEPES, and 2 MgATP (pH 7.2). During experiments, slices were superfused at 1.0 
mL/min with artificial cerebrospinal fluid containing the following (in millimolar): 
135 NaCl, 21 NaHCO3, 0.6 CaCl2, 3 KCl, 1.25 NaH2PO4, 1.8 MgSO4, and 10 D-glucose, 
aerated with 95% O2 and 5% CO2 (pH 7.4). Recordings were made from cortical 
layer II/III or V pyramidal neurons. For miniature excitatory post-synaptic current 
(mEPSC) recordings TTX was added to the solution. For cell-attached recordings, 
glass micropipettes (resistance, 2–5 MΩ) were filled with ACSF, and slices were bath 
perfused with the same solution. After a giga-ohm seal had been obtained, each cell 
was recorded under different conditions depending on the experiments for 4 min 
each: baseline in ACSF, GABA 200 μM. All cell-attached recordings were performed 
in the voltage-clamp mode, and the recording pipette was kept at 0 mV for all such 
recordings. Data from the whole 4 min of recording were analysed for quantification 
of spiking activity. 
 
 
TWO-PHOTON CHLORIDE IMAGING 
Imaging of neuronal intracellular Cl− in acute cortical slices was performed using the 
fluorescent indicator MQAE [N-(ethoxycarbonylmethyl)-6-methoxyquinolinium 
bromide]. MQAE dye detects Cl− ions via diffusion-limited collisional quenching, 
resulting in a concentration-dependent decrease in fluorescence emission after an 
increase in Cl− concentration. Ex vivo brain slices (prepared as described above for 
patch-clamp experiments) were incubated at 37 °C in the dark for 30 minutes in 
oxygenated ACSF containing 5 mM MQAE (Biotium). FLIM z-stacks were acquired 
with a TrimScope II two-photon upright microscope (LaVision BioTec) and a 20x NA 
1.0 objective (XLUMPFLN 20x, Olympus). Samples were excited with Ti:Sa pulsed 
laser tuned at 740 nm (Chameleon Ultra II, Coherent), and all emission light was 
collected with a TCSPC detector (FLIM x16, LaVision Biotec). Z-stacks started at least 
-30 ɥm from slice top position, in order to avoid any possible artifact due to cell non-
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viability, with z-step 3 ɥm and total z-stack size 80 ɥm. In a setup phase, standard z-
stack time-lapses with the same excitation conditions, collected with a standard 
PMT and 420/50 filter were recorded over 10-15 minutes in order to check slices 
viability and to assure that acquisition conditions did not induce any phototoxicity. 
We then drew a ROI for each cell, and FLIM data for each ROI was fitted to a single-
exponential lifetime curve with calculated offset (analysis software ImSpector Pro, 
LaVision Biotec). Data for each group was then statistically tested for Gaussian 
distribution and either t-test, parametric or non-parametric ANOVA depending on 
the datasets (Prism, GraphPad). 
 
 
BICINCHONIC ACID (BCA) ASSAY  
Protein content of brain cortices at different ages was assessed by bicinchoninic acid 
(BCA) assay, using BCA protein assay kit (Thermo Fischer Scientific). In the BCA 
method, BCA molecules chelate cuprous ion Cu+1, formed from Cu2+ reduction by 
proteins in alkaline environment. This chelation generates a purple-colored 
reaction product which has a strong absorbance at 562 nm, proportional to protein 
concentration in the sample. Sample absorbance was read through a 
spectrophotometer (Victor2 - 1420 multilabel counter, Wallac) set to 550 nm. 
 
 
WESTERN BLOTTING 
Cortices from E17 and P90 mice brains were homogenized in a glass-teflon potter 
using a solubilizing mix composed by sodium dodecyl sulphate 1% (SDS), 62.5 mM 
Tris-HCl at pH 6.8 and 290 mM sucrose. The homogenates were then centrifuged at 
1600 g at 4 °C for 15 minutes and the low speed supernatant was stored at -20 °C 
and subsequently used for SDS PAGE experiments. Cortex homogenates were 
separated by electrophoresis, blotted, and incubated with primary antibody, 
followed by HRP-conjugated secondary antibody (Jackson ImmunoResearch) and 
developed by Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). The 
following primary antibodies were used: monoclonal antibodies directed against 
PSD95 1:10000 (NeuroMab), Syntaxin1A 1:1000 (Sigma-Aldrich), SNAP25 1:1000 
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(Chemicon) and polyclonal antibodies directed against Calnexin 1:2000 (Sigma-
Aldrich), GAPDH 1:1000 (Synaptic Systems) vGLUT1 1:1000 (Synaptic Systems), 
vGAT 1:1000 (Synaptic Systems), KCC2 1:1000 (Millipore), NKCC1 1:1000 
(Millipore), MeCP2 1:1000 (Sigma-Aldrich). 
 
 
QUANTITATIVE REAL-TIME PCR  
Whole embryos obtained from GD9 injected dams and brain tissues from E17, P20 
and P90 offspring were used for real-time PCR analysis. Samples were homogenized 
prior to RNA extraction in 500 ɥl of TRI-reagent (Zymo research). Total RNA was 
isolated using the Direct-zol RNA MiniPrep isolation kit (Zymo research) according 
to the manufacturer’s protocol. The RNA was eluted with 25 μL DNase/RNAse-free 
water, quantified using NANOdrop 2000c spectrophotometer (Thermo Fisher 
Scientific) and optical density 260/280 nm ratios were determined. Reverse 
transcription was performed using 1 μg RNA with a High Capacity cDNA RT kit 
(Applied Biosystems). Real-time polymerase chain reaction (qRT-PCR) was 
performed using RT-PCR Viia7 (Applied Biosystems) in a final volume of 10 μl for 
SYBR Green technique (SensiFAST SYBR Lo-ROX, Bioline) and 20 μl for TaqMan 
technique (Gene Expression Master Mix, Life Technologies). Each gene was analysed 
at least in duplicate and data analysis was performed with the ΔΔCt method. All RNA 
levels were normalized to GAPDH or Actin where indicated. 
 
 
MATERNAL MAGNESIUM SULFATE SUPPLEMENTATION 
GD9 pregnant dams were used. The magnesium sulfate (MgSO4, Sigma-Aldrich) 
injection protocol included an initial subcutaneous loading dose of 270 mg/kg 
followed by maintenance doses of 57 mg/kg every 40 minutes for 4 hours. A second 
loading dose of 270 mg/kg was given at the end of the injection session. Control mice 
were injected with saline solution at the same volume and schedule (protocol 
adapted from Hallak 1999, [237]). Magnesium sulfate supplementation was 
performed just before Poly I:C/vehicle ip. injection at GD9. Four experimental 
groups were evaluated to assess the potential preventive effects of magnesium by 
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acting as immunomodulator and reducing inflammation at the maternal-fetal 
interface: MgSO4 (sc)+vehicle (ip); MgSO4 (sc)+Poly I:C (ip); vehicle (sc)+vehicle 
(ip); vehicle (sc)+Poly I:C (ip). 
 
 
PRIMARY CORTICAL CULTURES  
Primary neuronal cultures were prepared from E17 mice from Poly I:C or vehicle 
injected dams. Once obtained, cortices were chemically dissociated by treatment 
with 0.25% trypsin (Invitrogen) for 15 min at 37°C, followed by mechanical 
dissociation with a fire-polished Pasteur pipette. Dissociated cells were then plated 
on poly-L-lysine-treated (1 mg/ml, Sigma-Aldrich) 24 mm glass coverslips in 
Neurobasal (Invitrogen) containing 2% B27 (Invitrogen), 100U/ml penicillin, 100 
ɥg/ml streptomycin, 200 mM glutamine, 10 nM glutamate, as described in Brewer 
et al. [238], at densities ranging from 10x103 to 20x103 cells/cm2. Neuronal cultures 
were kept at constant temperature (37°C) in the presence of 5% CO2. At 3 days in 
vitro (DIV), half of the culture medium was replaced with fresh medium without 
glutamate to avoid excitotoxicity phenomena. Cells were then used for calcium 
imaging and chloride imaging at 6 DIV and electrophysiological recordings and 
immunocytochemical staining at 14 DIV. 
 
 
CELL CULTURE ELECTROPHYSIOLOGY 
Miniature excitatory and inhibitory post-synaptic currents (mEPSCs and mIPSCs) 
were recorded in the presence of tetrodotoxin (TTX, Tocris); a reversible blocker of 
sodium channels that avoids the generation of action potentials. In presence of TTX 
the mPSCs incur spontaneously, induced by the release of a single vesicle. Thus, they 
correspond to the event generated from a quantum of neurotransmitter that 
interacts with postsynaptic receptors. Whole-cell patch-clamp recordings were 
obtained from 13-14 DIV cortical neurons with an Axopatch 200B amplifier and 
pClamp-10 software (Axon Instruments). Recordings were performed in the 
voltage-clamp mode. Currents were sampled at 2 kHz and filtered at 2-5 kHz. 
External solution [Krebs'-Ringer's-HEPES (KRH)] had the following composition (in 
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mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2 CaCl2, 6 glucose, and 25 HEPES-
NaOH, pH 7.4. mEPSCs and mIPSCs were recorded in the presence of 1 μM 
tetrodotoxin (TTX). Recording pipettes were fabricated from capillary glass (World 
Precision Instruments) using a two-stage puller (Narishige) and had tip resistances 
of 3-5M when filled with the intracellular solution of the following composition (in 
mM): 130 K-gluconate (or Cs-Gluconate for IPSCs & mEPSCs), 10 KCl, 1 EGTA, 10 
HEPES, 2 MgCl2, 4 MgATP and 0.3 Tris-GTP. Neurons were held at -70 or + 10 mV to 
identify, respectively, excitatory or inhibitory miniature events. Recordings were 
performed at room temperature. Off-line analysis of mEPSCs and mIPSCs have been 
performed using Clampfit-pClamp-10 software and events had to exceed a threshold 
of two times the SD of the baseline noise. Spontaneous burst activity was recorded 
in whole-cell voltage-clamp configuration in the absence of TTX while Multi Units 
were recorded in cell-attached configuration. 
 
 
INTRACELLULAR CALCIUM MEASUREMENTS IN NEURONAL 
CULTURES 
5-6 DIV cortical cultures were loaded with 5 μM Fura-2 pentacetoxymethylester in 
KRH for 30 minutes at 37 °C, washed in the same solution and transferred to the 
recording chamber of an inverted microscope (Axiovert 100, Zeiss, Oberkochen, 
Germany) equipped with a calcium imaging unit. After a period of baseline 
acquisition, neurons were stimulated with GABA 100 μM and responses were 
recorded. Fura-2 fluorescence images were analysed with TILLvision software 
(TILL Photonics). After excitation at 340 and 380 nm wavelengths, emitted light was 
acquired at 505 nm at a rate of 1–4 Hz. Temporal Ca2+ intensity profiles (expressed 
as F340/380 fluorescence ratio) were calculated in discrete areas of interest from 
image sequences. “Ratio changes” indicate the amplitude of the peak of Ca++ 
responses, thus indicating the depolarizing GABA activity.  
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INTRACELLULAR CHLORIDE MEASUREMENTS IN NEURONAL 
CULTURES 
6 DIV cortical cultures were loaded with 5 μM MQAE (Biotium) in KRH. MQAE is a 
6-methoxyquinolinium derivative and it is used as a fluorescent indicator for 
intracellular chloride. This dye detects the ion via diffusion-limited collisional 
quenching. MQAE has greater sensitivity to Cl- and a higher fluorescence quantum 
yield than SPQ; consequently, it is currently the more widely used of the two 
indicators. After 1 hour incubation at 37 °C, neurons were washed in KRH and 
transferred to the recording chamber of an inverted microscope (Olympus) 
equipped with a CellR imaging station. All excitation and acquisition parameters 
were kept constant throughout the experiments. Image analysis was performed 
using Xcellence software (Olympus) by measuring the mean fluorescent intensity of 
regions of interest.  
 
 
IMMUNOCYTOCHEMICAL STAINING 
Primary cortical cultures were fixed with 4% paraformaldehyde and 4% sucrose in 
0,12 M phosphate buffer for 20 min at 37°C and immunofluorescence staining was 
carried out as previously described [239]. Images were acquired using a Zeiss LSM 
510 META confocal microscope with 60X objective. Immunofluorescence staining 
was carried out using the following antibodies: guinea pig anti-vGlut1 (1:1000), 
rabbit anti-vGAT (1:1000), both from Synaptic System. Secondary antibodies were 
conjugated with Alexa-488, Alexa-555 or Alexa-633 fluorophores (Invitrogen). The 
number of vGAT and vGlut1 positive puncta have been counted after the detection 
of an appropriate threshold which was set to 2.5-fold the level of background 
fluorescence referring to diffuse fluorescence within dendritic shafts. Fluorescence 
images processing and analyses were performed with ImageJ Software (National 
Institutes of Health). 
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CHROMATIN IMMUNOPRECIPITATION 
Cortices of P20 mice have been dissected and rapidly incubated in 1% formaldehyde 
for 15 minutes at RT for cross-linking and then transferred in 0.125M glycine for 10 
minutes and homogenized in the appropriate lysis buffer (10 mM Tris- HCl pH 8; 1 
mM EDTA, 0.5 mM EGTA, 100 mM NaCl, 0.1% Na-deoxy-cholate, 0.5% N-
laurylsarcosine) containing protease inhibitors and PMSF 0.2 mM. Lysates were 
then sonicated to generate fragments with an average length of ~500-200 bp, as 
determined empirically by agarose gel electrophoresis of the fragmented chromatin 
sample. The samples were then incubated with protein G Dynabeads (Invitrogen) 
bound to REST (Millipore) and MeCP2 pAb (Sigma-Aldrich) at 4°C for 6 hours. 
Immunoprecipitation was then performed overnight with 25 ɥg of sonicated 
chromatin in 600 µl of lysis buffer containing Triton 1%, PMSF 0.2 mM and 1.2 µg of 
anti-MeCP2 pAb bound to. A sample without Igg was included as a control. The beads 
were then washed sequentially at 4°C (for 7 minutes each) with 800 µl of low salt 
buffer (0.1% SDS, 2 mM EDTA, 1% Triton, 20 mM Tris-HCl pH 8, 150 mM NaCl), high 
salt buffer (0.1% SDS, 2 mM EDTA, 1% Triton, 20 mM Tris-HCl pH 8, 500 mM NaCl 
and TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA pH 8.0), then again with low salt 
buffer and with high salt buffer. At the end the beads were washed with TE-NaCl 
buffer (10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl). Elution was performed in 100µl 
of fresh elution buffer (1% SDS, 0.1 M NaHCO3). Cross-linking was reversed 
overnight at 65°C. After cross-link reversal, 240 µg of Ribonuclase A (Sigma-Aldrich) 
were added to each sample to completely eliminate the RNA and the samples were 
incubated for 40 minutes at 37°C. The samples were then digested with 20 µg of 
proteinase K (Sigma-Aldrich) for 1 hour at 56°C, and DNA was recovered by 
standard methods in 20 µl of 10 mM Tris-HCl pH 8. KCC2 promoter was then 
analysed by quantitative real-time PCR.  
 
 
STATISTICAL ANALYSIS 
Pairwise comparisons between treatments were assessed with Student’s t-test. One-
way ANOVA with repeated measures or 2-way ANOVA as between subject factor 
were used. Post hoc analysis was done using Tukey’s Bonferroni’s or Holm Sidak’s 
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post hoc tests. Unless otherwise stated, average data are expressed as mean ± SEM. 
Data were expressed as means ± SEM for the number of cells or animals (n). The 
differences were considered to be significant, if p< 0.05 (indicated by one asterisk), 
p< 0.01 (double asterisks), p< 0.005 (triple asterisks). All statistical analyses were 
done with software Prism, version 6 (GraphPad). 
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